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ABSTRACT
Clinicians and researchers alike are increasingly interested in how best to personalize interventions.
A dynamic treatment regimen (DTR) is a sequence of pre-specified decision rules which can be
used to guide the delivery of a sequence of treatments or interventions that are tailored to the
changing needs of the individual. The sequential multiple-assignment randomized trial (SMART)
is a research tool which allows for the construction of effective DTRs. SMARTs are multi-stage
randomized trials in which some or all participants are randomized more than once, with each
randomization corresponding to an open scientific question which will aid in the development of
a high-quality DTR. In this dissertation, we develop a suite of tools which aid investigators in
the design and analysis of SMARTs with continuous, longitudinal outcomes which are collected
throughout the multiple stages of the trial.
We begin by deriving easy-to-use formulae for computing the total sample size for three
common two-stage SMART designs in which the primary aim is to compare mean end-of-study
outcomes for two embedded DTRs which recommend different first-stage treatments. The formulae
are derived in the context of a regression model which leverages information from a longitudinal
outcome collected over the entire study. We show that the sample size formula for a SMART can be
written as the product of the sample size formula for a standard two-arm randomized trial, a deflation
factor that accounts for the increased statistical efficiency resulting from a longitudinal analysis, and
an inflation factor that accounts for the design of a SMART. The SMART design inflation factor is
typically a function of the anticipated probability of response to first-stage treatment. We review
modeling and estimation for DTR effect analyses using a longitudinal outcome from a SMART, as
well as the estimation of standard errors. We also present estimators for the covariance matrix for
a variety of common working correlation structures. Methods are motivated using the ENGAGE
xi
study, a SMART aimed at developing a DTR for increasing motivation to attend treatments among
alcohol- and cocaine-dependent patients.
Randomized trials are often constrained by limited financial resources; SMARTs are no differ-
ent. The longitudinal deflation factor we develop allows for reduction in sample size requirements
via both within-person correlation and the repeated measurements of the outcome over time. We
provide guidance on how to balance sample size and the number of measurement occasions to
minimize total cost of recruitment and measurement while achieving a target power. Finally, we
introduce a procedure to generate data from a longitudinal SMART that will achieve an arbitrary
desired covariance structure on potential outcomes, averaged over response status. This procedure,
as well as user-friendly sample size tools which solve the cost optimization problems, are available
in an R package called longsmart.
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CHAPTER 1
An Introduction to Dynamic Treatment Regimens
and Sequential, Multiple-Assignment, Randomized
Trials
In practice, interventions often involve sequences of treatments that are adapted to an individual’s
changing needs. A single, fixed treatment may or may not be adequately effective for all individuals
at all times; indeed, heterogeneity of treatment effects across people often exists (Longford 1999;
Gail and Simon 1985). Chronic conditions which wax and wane in severity may require an
intervention strategy which adjusts treatment according to changing severity over time.
Clinical practice typically involves the provision of treatment, some follow-up period, then
modification of treatment to better suit the individual’s needs, if necessary. However, open questions
often remain as to the protocolization of this sequence. For example, “[i]gnorance of whether or
how to change psychotherapies is a major and persisting gap in psychiatric knowledge” (Markowitz
and Milrod 2015).
Dynamic treatment regimens (DTRs) operationalize clinical decision-making by recommend-
ing particular treatments to certain subsets of patients at specific times (Chakraborty and Moodie
2013). DTRs are sequences of pre-specified decision rules leading to courses of treatment which
adapt to a patient’s changing needs (Kosorok and Moodie 2015). Consider the following example
DTR which was designed to increase engagement with an intensive outpatient rehabilitation pro-
gram (IOP) for patients with alcohol and/or cocaine dependence: “Within a week of the participant
becoming non-engaged in the IOP, provide two phone-based sessions focused on helping the patient
re-engage in the IOP. At week 8, look back at the participant’s engagement pattern over the past
eight weeks. If the participant continued to not engage (i.e., did not respond to the intervention),
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provide a second pair of phone-based sessions, this time focused on facilitating personal choice (i.e.,
highlighting various treatment options the patient can choose from in addition to IOP). Otherwise,
for those who did engage with the intervention, provide no further contact” (McKay et al. 2015).
Notice that the DTR recommends intervention strategies for both engaged and non-engaged partic-
ipants at week 8. Alternative names for DTRs include adaptive treatment strategies (Wallace and
Moodie 2014; Ogbagaber, Karp, andWahed 2016) and adaptive interventions (Almirall et al. 2014;
Nahum-Shani et al. 2012a), among others.
Scientists often have questions about how best to sequence and individualize interventions in
the context of a DTR. Sequential, multiple-assignment, randomized trials (SMARTs) are one type of
randomized trial design that can be used to answer questions at multiple stages of the development
of high-quality DTRs (Lavori and Dawson 2000, 2004; Murphy 2005). The characteristic feature
of a SMART is that some or all participants are randomized more than once, often based on
previously-observed covariates. Each randomization corresponds to a critical question regarding
the development of a high-quality DTR, typically related to the type, timing, or intensity of
treatment. SMARTs have been employed in a variety of fields, including oncology (Auyeung et
al. 2009; Kidwell 2014; Thall 2015), surgery (Diegidio et al. 2017; Hibbard et al. 2018), substance
abuse (Murphy et al. 2007), and autism (Kasari et al. 2014).
In this chapter, we introduce and motivate the study of DTRs and SMARTs. We begin by
formally defining DTRs, then discuss how they can be studied using a SMART.We present a variety
of SMART designs, and discuss motivations for each.
1.1 Dynamic Treatment Regimens (DTRs)
A DTR is a sequence of functions (“decision rules”), each of which takes as inputs a person’s
history up to the time of the current decision (including baseline covariates, adherence, responses
to previous treatments, etc.) and outputs a recommendation for the next treatment (Murphy 2005).
Formally, suppose we wish to construct a DTR which recommends 𝑀 treatments, 𝑎1, . . . , 𝑎𝑀 , to
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each individual. After the 𝑗 th treatment, the DTR will have recommended the sequence ?̄? 𝑗 ={
𝑎1, 𝑎2, . . . , 𝑎 𝑗
}
. Let 𝑆 𝑗 (?̄? 𝑗−1) denote information collected in the period after providing treatment
𝑎 𝑗−1 until immediately prior to the provision of treatment 𝑎 𝑗 . This includes any outcomes and
covariates which may be observed, as well as previous treatment assignments. 𝑆1 contains pre-
treatment information. Note that 𝑆 𝑗 (?̄? 𝑗−1) is indexed by the history of treatment assignments
made up to, but not including, the time at which 𝑎 𝑗 is assigned, reflecting the fact that different
values of the covariates may be observed depending on the assigned sequence of treatments. We
use 𝑆 𝑗 (?̄? 𝑗−1) = {𝑆1, 𝑆2(𝑎1), . . . , 𝑆 𝑗−1(?̄? 𝑗−2), 𝑆 𝑗 (?̄? 𝑗−1)} to represent the “history” until the time at
which 𝑎 𝑗 is provided.
A decision rule 𝜑 𝑗 is a function of 𝑆 𝑗 (?̄? 𝑗−1) which outputs a recommendation for subse-
quent treatment 𝑎 𝑗 . An 𝑀-stage dynamic treatment regimen is a sequence of 𝑀 decision rules
{𝜑1, . . . , 𝜑𝑀} (Murphy 2005). The times in a patient’s care when a decision is made is called a
decision point. These can occur at scheduled intervals, after a specific number of clinic visits, or
be event-based, such as the point at which a patient fails to respond or adhere to a treatment. The
timing of decision points should be based on scientific or practical considerations which inform
when treatment may need to be modified.
The information 𝑆 𝑗 (?̄? 𝑗−1) often contains covariates which inform the recommendation to
subsequent treatment 𝑎 𝑗 . These covariates are called “tailoring variables.” These could be static
characteristics (e.g., demographic factors, history of prior treatment, etc.) or time-varying partici-
pant information, such as disease severity, which may vary based on ?̄? 𝑗−1.
Consider the example two-stageDTRabove. The clinician experiences twodecision points: the
first is at treatment initiation and the second occurs after eight weeks, at which point the individual
is identified as a “responder” or “non-responder” based on their engagement. There is a single
treatment option at the first decision point, and two options at the second decision point (motivational
interviewing focused on facilitating personal choice, or no further contact). The recommended first-
stage treatment for all patients is a phone-based session with a focus on re-engagement with the IOP;
𝜙1(𝑆1) is constant in 𝑆1. At week 8, each participant’s history of engagement is assessed, and an
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appropriate second-stage treatment is recommended. For participants who have shown a pattern of
continued non-engagement (non-responders), the recommended second-stage treatment is a second
phone-based session focusing on personal choice. For all other participants (responders), the DTR
recommends no further contact. Here, the tailoring variable contained in 𝑆2(𝑎1) is an indicator
as to whether or nor the participant demonstrated a pattern of continued non-engagement prior to
week 8.
In this dissertation, we will consider only two-stage DTRs. Further, we focus on binary
tailoring variables, which we will abbreviate to “response” or “non-response”. Since a DTR
recommends treatments to both responders and non-responders, we can denote a DTR with a triple
of the form (𝑎1, 𝑎2R, 𝑎2NR), where 𝑎1 is an indicator for the recommended first-stage treatment, 𝑎2R
an indicator for the second-stage treatment recommended for responders, and 𝑎2NR the second-stage
treatment recommended for non-responders.
Researchers interested in developing high-quality DTRs often have unanswered questions that
cannot necessarily be answered based on existing literature, or expert clinical opinion. These
questions typically concern the relative effectiveness of different DTRs, the relative effectiveness of
different DTR components at specific stages, how the intervention components at different stages
work with (or against) each other, and questions related to how best to tailor treatment at different
stages of intervention. Common questions are about which treatment option the DTR should
begin with, how to modify the initial treatment for non-responders, how to best define or monitor
individuals for response/non-response, and the timing of decision points and thus interventions.
These questions can be addressed using a sequential, multiple-assignment randomized trial, or
SMART.
4
1.2 Sequential Multiple-Assignment Randomized Trials
(SMARTs)
A SMART is a type of randomized trial in which some or all participants are randomized more than
once, the goal of which is typically to develop a high-quality DTR. In a SMART, all participants
move through multiple stages of treatment. At each stage, participants may be randomized to a set
of feasible treatment options. These randomizations correspond to scientific questions about the
development of an effective DTR. The treatment options to which a participant is randomized at
each stage may depend on participant characteristics via a tailoring variable or prior treatment. We
consider two-stage SMARTs in which the primary outcome is continuous and repeatedly measured
in participants over the course of the study.
Most SMARTs contain “embedded” DTRs; that is, by design, participants in a SMART may
be assigned to treatments which are consistent with recommendations made by one or more DTRs.
Often, subsequent randomizations in a SMART are restricted to particular groups of participants
based on an embedded tailoring variable, which is chosen based on scientific, ethical, or practical
considerations. For example, in oncology, it would be unethical to randomize patients who do not
respond to a high dose of chemotherapy to an intervention which would increase the dose beyond a
known toxicity threshold. Instead, investigators may choose to not re-randomize these individuals
to a higher dose.
We consider SMARTs in which each randomization is between two possible interventions,
and where the tailoring variable is binary. In Figure 1.1, we introduce three common two-stage
SMART designs which vary in the subsets of participants who are re-randomized after the first
stage. To our knowledge, these designs are representative of the majority of the SMARTs in the
field to date.
In design I, all participants are re-randomized. There are eight DTRs embedded in this design:
for example, the DTR which starts by recommending A, then recommends C for responders and
F for non-responders. Using the notation above and the indices in figure 1.1, this DTR would
5































(I) All participants are re-randomized, regardless of response status.

























(II) The second randomization is restricted to only non-responders.























(III) The second randomization is restricted to only non-responders to
treatment A.
Figure 1.1: Three commonly-used two-stage SMART designs. Each design varies in choice of which subsets of
participants are re-randomized. Circled R indicates randomization, capital letters indicate (potentially non-unique)
treatments, and 𝑎– provides a coding system used to index embedded DTRs.
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be written (1, 1, -1). SMARTs of this form have been run in the fields of drug dependence
(Oslin 2005; Fitzsimons et al. 2015), smoking cessation (Fu et al. 2017), and childhood depression
(Eckshtain 2013), among others. Often, motivation for re-randomizing all participants arises out
of open scientific questions regarding both a maintenance therapy for responders and a “rescue”
intervention for non-responders.
SMARTs using design II restrict the second randomization to only non-responders; that is,
only participants who have a certain value of the tailoring variable (here, “non-response”) are re-
randomized. This might be motivated by an open question regarding second-stage treatment only
among non-responders (i.e., the follow-up intervention for responders may be well-established).
Design II is perhaps the most common SMART design, and is often referred to as the “prototypical”
SMART (NeCamp, Kilbourne, and Almirall 2017). It has been utilized in the study of ADHD
(Pelham et al. 2016), adolescent marijuana use (Budney 2014), alcohol and cocaine dependence
(McKay et al. 2015), and more. There are four embedded DTRs in this design. Because responders
are not re-randomized, 𝑎2R is set to zero for all embedded DTRs.
In design III, re-randomization is restricted to only non-responders who receive a particular
first-stage treatment. This design might be used when one of the first-stage interventions involves
a top-of-the-line treatment that, for practical reasons, cannot be intensified in the second stage. For
the individuals randomized to this first-stage treatment, there may only be one option for subsequent
intervention, regardless of their value of the tailoring variable. SMARTs of this type have been used
to investigate cognition in children with autism spectrum disorder (Kasari et al. 2014; Almirall
et al. 2016) and implementation of a re-engagement program for patients with mental illness
(Kilbourne et al. 2013). There are three DTRs embedded in this design. Note that, as in design II,
responders are not re-randomized, so 𝑎2R is set to zero for all embedded DTRs. Furthermore, 𝑎2NR
is set to zero when 𝑎1 = −1, as non-responders to treatment B are not re-randomized.
As stated before, the goal of SMART designs is to aid the development of DTRs. Data
collected in a SMART can be used to answer questions concerning which intervention option
to provide at critical decision points during care. Common primary aims for SMARTs include a
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comparison of first-stage treatment options averaged over subsequent interventions, or a comparison
of second-stage intervention options among responders, averaged over the first-stage definition of
non-response; similarly for non-responders. Questions can also focus on comparisons of the DTRs
embedded in a SMART. An example would be to compare the DTR shown in Figure 1 (embedded
DTR 2) to embedded DTR 5 based on proportion of days abstinent from alcohol at the end of the
study. This type of comparison may be used to investigate the difference between, say, the most
and least intensive DTRs, or the most and least expensive.
Each of the SMART designs discussed above is motivated by a different set of scientific
questions at multiple stages of a DTR. Data collected in a SMART can be used to answer questions
concerning which intervention option to provide at critical decision points during care. Questions
can also focus on comparisons of the DTRs embedded in a SMART. Because each randomization
in a SMART corresponds to an open question about subsequent treatment recommendations, and
the defining characteristic of a SMART is that some or all participants are randomized more than
once, questions that do not involve multiple stages of treatment do not, by themselves, motivate a
SMART. Almirall et al. (2018) describe several “singly-randomized” alternatives to SMARTs in
the context of research on DTRs.
To illustrate ideas, we use ENGAGE, illustrated in figure 1.2. ENGAGE is a SMART designed
to study the effects of offering cocaine- and/or alcohol-dependent patients who did not engage in an
IOP phone-based sessions either geared toward re-engaging them in an IOP or offering a choice of
treatment options (McKay et al. 2015). The study recruited 500 cocaine- and/or alcohol-dependent
adults who were enrolled in an IOP and failed to attend two or more sessions in the first two
weeks. ENGAGE is modeled on design II. In the context of figure 1.1, treatment A was two phone-
based motivational interviews focused on reengaging the participant with the IOP (“MI-IOP”);
treatment B was two phone-based motivational interviews geared towards helping the participant
choose and engage with an intervention of their choice (“MI-PC”). Participants who exhibited
a pattern of continued non-engagement after eight weeks were considered non-responders, and
re-randomized to receive either MI-PC (treatments D and G) or no further contact (treatments E
8






















Figure 1.2: The ENGAGE SMART. Circled R indicates randomization with probability 0.5. “MI-IOP” refers to
motivational interviewing with focus on intensive outpatient program; “MI-PC” to motivational interviewing with
focus on patient choice; “NFC” to no further contact. Subgroups identify particular treatment paths which participants
may follow.
and H). Responders were provided no further contact (treatments C and F). Following the coding
in figure 1.1, the example DTR on page 1 is labeled (1, 0, 1). The other embedded DTRs are given
in table 1.1.
An important continuous outcome in ENGAGE is “treatment readiness”. This is a measure of
a patient’s willingness and ability to commit to active participation in a substance abuse treatment
program. The score ranges from 8 to 40 and is coded so that higher scores indicate greater treatment
readiness. Measurements are taken at baseline, and 4, 8, 12, and 24 weeks after program entry.
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Table 1.1: Embedded DTRs in the ENGAGE SMART. ENGAGE is depicted in figure 1.2. “MI-IOP” refers to
motivational interviewing with focus on intensive outpatient program; “MI-PC” to motivational interviewing with
focus on patient choice; “NFC” to no further contact. “Subgroups” are in reference to figure 1.2. The final column










1 MI-IOP NFC MI-PC A, B (1, 0, 1)
2 MI-IOP NFC NFC A, C (1, 0,−1)
3 MI-PC NFC MI-PC D, E (−1, 0, 1)
4 MI-PC NFC NFC D, F (−1, 0,−1)
1.2.1 Considerations for Designing SMARTs
ENGAGE contains four embedded DTRs. Notice that responders to a particular first-stage inter-
vention are consistent with both embedded DTRs which recommend that intervention. ENGAGE
is conceptually similar to a 2 × 2 (fractional) factorial design (Murphy and Almirall 2009; Collins,
Nahum-Shani, and Almirall 2014; Vock and Almirall 2018). The first factor is MI-IOP vs. MI-PC;
the second factor is restricted to non-responders and is MI-PC vs. no further contact.
Two key differences from factorial designs are the sequential nature of treatment delivery in
a SMART, as well as the possible restriction of certain treatment options to participants based on
their response status. Scientific questions which motivate a SMART are asked in the context of a
sequence of treatments which are delivered at multiple points in time: this is not typically captured
by a standard factorial design. Additionally, SMARTswhich contain an embedded tailoring variable
usually offer different sets of treatment options to responders and non-responders. Similarly, first-
stage treatment assignment may determine whether individuals are re-randomized, as in design III
SMARTs. These SMARTs are therefore not fully crossed designs (Nahum-Shani et al. 2012a).
SMARTs often include standard-of-care control groups. Most commonly, this is done by
embedding a standard-of-care intervention as one of the DTRs. For instance, in design II, one
of the embedded DTRs may be a DTR that is commonly used in practice or could recommend
standard-of-care throughout. This type of SMART would allow for comparisons of the other
embedded DTRs against this standard-of-care DTR.
An important consideration in the design of a SMART is the choice of embedded tailoring
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variable, if included. Embedding a tailoring variable into the trial also embeds it into any DTRs
the trial is able to study, so its inclusion should be well-justified based on scientific, ethical, or
practical considerations. The tailoring variable is a component of the DTR. As such, its operating
characteristics are part of the intervention aswell as the trial. Therefore, tailoring variables should be
relatively easily measured in a clinical setting and reliably identify responders and non-responders.
A variable which may “misclassify” individuals is not a good choice of tailoring variable, as it may
make assignment to subsequent treatment unsystematic. This is an issue that should be anticipated
and designed around, rather than corrected post hoc.
In a SMART, the same cohort of individuals participates in all stages of treatment and a
single study consent process is used for all these individuals (prior to the first stage randomization).
SMARTs should not employ multiple consents (e.g., one at each randomization point); doing so
could severely limit the ability to make inferences about the relative effects of the DTRs embedded
in a SMART. Rather, the single consent process should inform participants of all possible treatment
sequences to which they may be assigned during the study. Because the goal of a SMART is
to develop a high-quality DTR, participants in the trial should experience the DTR as close to a
real-world implementation as possible; a re-consent process would detract from this goal. Should
they wish, investigators could randomize participants to DTRs at the start of the trial, though this
should be carefully blinded to avoid expectancy effects: participants should not have knowledge of
their future treatment assignments.
Importantly, SMARTs are typically not adaptive trial designs despite using similar terminology
(e.g., adaptive interventions, etc.) (Meurer, Lewis, and Berry 2012). An adaptive trial is a multi-
stage study in which ongoing patient information is used to modify the design of the trial as data
are collected (Dragalin 2006). By contrast, SMARTs are usually fixed designs in which the goal
is to identify a sequence of treatments which adapt to the participant’s changing needs. Recently,




Estimation and Sample Size for SMARTs with
Continuous Longitudinal Outcomes
This work originally appeared as Seewald et al. (2020).
The comparison of two embedded DTRs which recommend different first-stage treatments is a
common primary aim for a SMART (Nahum-Shani et al. 2012a). There exist data analytic methods
for addressing this aim when the outcome is continuous (Nahum-Shani et al. 2012a), survival (Li
and Murphy 2011), binary (Kidwell et al. 2018), cluster-level (NeCamp, Kilbourne, and Almirall
2017), and longitudinal (Lu et al. 2016; Li 2017). A key step in designing a SMART, as with any
randomized trial, is determining the sample size needed to be able detect a desired effect with given
power. However, there is no existing method for determining sample size for such a comparison
when the outcome is continuous and longitudinal.
Often, SMARTs involve repeated measurements of a continuous outcome spaced throughout
the trial. This might involve a measurement at baseline, one or more measurements in the first stage
of the trial (before assessment of the tailoring variable and subsequent re-randomization), and one
or more measurements in the second stage. In this chapter, we begin by reviewing the work of Lu
et al. (2016), which developed models and an estimation procedure for SMARTs with longitudinal
outcomes. We then extend that work by offering more detailed guidance on the estimation of model
parameters used in computing quantities of interest on which to compare two embedded DTRs.
Finally, we present sample size formulae for SMARTs in which the primary aim is to compare
the mean end-of-study outcomes for two embedded DTRs which recommend different first-stage
treatments and which satisfy certain design constraints.
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Our primary contribution is tractable sample size formulae for SMARTs with a continuous
longitudinal outcome in which the primary aim is an end-of-study comparison of two DTRs which
recommend different first-stage treatments. Additionally, we present estimators for parameters in
the working covariance matrix used in the analysis methods developed by Lu et al. (2016).
Sections 2.1 and 2.2 review the modeling and estimation procedures introduced by Lu et
al. (2016) and extends it by developing estimators for various working covariance structures in
section 2.2.3. In section 2.3, we develop and present sample size formulae for SMARTs in which
the primary aim is a comparison of two embedded DTRs which recommend different first-stage
treatments using a continuous longitudinal outcome. The sample size formulae are evaluated via
simulation in section 2.4.
2.1 Marginal Mean Model
Consider a SMART design with embedded DTRs labeled by (𝑎1, 𝑎2R, 𝑎2NR). Suppose we have a
longitudinal outcome𝒀 𝑖 = (𝑌𝑖,1, . . . , 𝑌𝑖,𝑇 ), 𝑖 = 1, . . . , 𝑛, observed such that𝑌𝑖, 𝑗 is measured for each
of 𝑛 participants at each of 𝑗 = 1, . . . , 𝑇 measurement occasions
{
𝑡 𝑗 : 𝑗 = 1, . . . , 𝑇 ; 𝑡1 < . . . < 𝑡𝑇
}
.
We do not require that these measurements be equally-spaced, though they must be common to




= {0, 4, 8, 12, 24}. There are
𝑇1 = 3 measurements in stage 1 (note that this includes baseline) and 𝑇2 = 2 in stage 2. Define
𝑡∗ = 𝑡𝑇1 to be the time of the measurement taken immediately before the assessment of response
status and second randomization. In ENGAGE, 𝑡∗ = 𝑡3 = 8. Let 𝑿𝑖 be a vector of mean-centered
baseline covariates, such as age at baseline, sex, etc., for the 𝑖th individual.
We are interested in E[𝑌 (𝑎1,𝑎2R,𝑎2NR)
𝑗
| 𝑿], the marginal mean outcome at time 𝑡 𝑗 under DTR
(𝑎1, 𝑎2R, 𝑎2NR) conditional on 𝑿. This is the mean outcome at the 𝑗 th measurement occasion
had all individuals with characteristics 𝑿 been offered DTR (𝑎1, 𝑎2R, 𝑎2NR). Recall that a DTR
recommends treatments for both responders and non-responders; therefore, E[𝑌 (𝑎1,𝑎2R,𝑎2NR)𝑡 | 𝑿] is
marginal over response status. Note that 𝑌 (𝑎1,𝑎2R,𝑎2NR)
𝑖, 𝑗
is a potential outcome, the value of 𝑌𝑖, 𝑗 that
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would be observed at time 𝑡 𝑗 had participant 𝑖 been treated according to the DTR (𝑎1, 𝑎2R, 𝑎2NR).
We impose amodeling assumption onE[𝑌 (𝑎1,𝑎2R,𝑎2NR)
𝑗






(𝑿; 𝜽), where `(𝑎1,𝑎2R,𝑎2NR)
𝑗
(𝑿; 𝜽) is a marginal structural mean model with unknown
parameters 𝜽 = (𝜼>, 𝜷>)>. We use 𝜼 to represent a column vector of parameters indexing baseline
covariates, and 𝜷 is a column vector of coefficients on terms involving treatment effects; we discuss
in more detail below. As noted by Lu et al. (2016), the sequential nature of treatment delivery
in SMARTs may suggest constraints on the form of `(𝑎1,𝑎2R,𝑎2NR)
𝑗
(𝑿; 𝜽) which depend, in part, on
the design of the SMART. For instance, in ENGAGE, at time 𝑡 = 0, no treatments have been
assigned, so all DTRs share a common mean. At times 𝑡 = 4 and 𝑡 = 8, the four embedded DTRs
differ only by recommended first-stage treatment; thus there are two means of 𝑌 (𝑎1,𝑎2R,𝑎2NR)
𝑗
at each
measurement occasion 2 < 𝑗 ≤ 𝑇1. Finally, for times 𝑡 > 𝑡∗ = 8 (𝑇1 < 𝑗 ≤ 𝑇), each DTR has a
different mean 𝑌 (𝑎1,𝑎2R,𝑎2NR)
𝑗
.
An example marginal structural mean model for ENGAGE (and, more generally, design II),




(𝑋1; 𝜽) = [1𝑋1 + 𝛽0 + 1{𝑡 𝑗≤𝑡∗}
(





∗ + 𝛽2𝑡∗𝑎1 + 𝛽3(𝑡 𝑗 − 𝑡∗) + 𝛽4(𝑡 𝑗 − 𝑡∗)𝑎1




where 1{𝐸} is the indicator function for the event 𝐸 . Similarly, for design I, a saturated marginal




(𝑿; 𝜽) = 𝜼>𝑿 + 𝛽0 + 1{𝑡 𝑗≤𝑡∗}
(





∗ + 𝛽2𝑡∗𝑎1 + 𝛽3(𝑡 𝑗 − 𝑡∗) + 𝛽4(𝑡 𝑗 − 𝑡∗)𝑎1 + 𝛽5(𝑡 𝑗 − 𝑡∗)𝑎2R









(𝑿; 𝜽) = 𝜼>𝑿 + 𝛽0 + 1{𝑡 𝑗≤𝑡∗}
(





∗ + 𝛽2𝑡∗𝑎1 + 𝛽3(𝑡 𝑗 − 𝑡∗) + 𝛽4(𝑡 𝑗 − 𝑡∗)𝑎1 + 𝛽5(𝑡 𝑗 − 𝑡∗)1{𝑎1=1}𝑎2𝑁𝑅
)
. (2.3)















𝑡 𝑗 − 𝑡𝑘
| 𝑿
 , 𝑗 , 𝑘 ≤ 𝑇1, 𝑗 ≠ 𝑘. (2.4)
This represents the difference in slopes of expected treatment readiness in the first stage of the
SMART between DTRs starting with different first-stage treatments (second-stage treatment is
arbitrary, as 𝑡 < 𝑡∗). Also, we can interpret [1 as the difference in expected outcome 𝑌 (𝑎1,𝑎2R,𝑎2NR)𝑗
associated with a one-unit difference in baseline covariate 𝑋1, marginal over all embedded DTRs.
2.2 Estimation
2.2.1 Observed Data
Suppose we have data arising from a SMART with 𝑛 participants. Let 𝐴𝑖,1 ∈ {−1, 1} be a random
variable which indicates first-stage treatment randomly assigned to participant 𝑖 (𝑖 = 1, . . . , 𝑛), and
let 𝑅𝑖 ∈ {0, 1} indicate whether the 𝑖th participant responded to 𝐴𝑖,1, in which case 𝑅𝑖 = 1, or not, so
𝑅𝑖 = 0. Define 𝐴𝑖,2 ∈ {−1, 1} to be the randomly-assigned second-stage treatment. Throughout, we
use uppercase 𝐴 to denote random treatment assignments; lowercase 𝑎’s are non-random indices
used to denote embedded DTRs.
In design II, since only non-responders are re-randomized, we set 𝐴𝑖,2 = 0 for responders;
similarly for design III. We observe a continuous outcome𝑌𝑖, 𝑗 for each participant at each measure-
ment occasion 𝑡 𝑗 , 𝑗 = 1, . . . , 𝑇 . In general, the data collected on the 𝑖th individual over the course
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of the study are of the form
(
𝑿𝑖, 𝑌𝑖,0, 𝐴𝑖,1,𝒀 𝑖,1:𝑇1 , 𝑅𝑖, 𝐴𝑖,2,𝒀 𝑖,𝑇1+1:𝑇
)
,
where 𝒀 𝑖, 𝑗 :𝑘 is a vector consisting of all values of the outcome observed for the 𝑖th participant at
measurement occasions 𝑗 through 𝑘 .
2.2.2 Estimating Equations
Our goal is to estimate and make inferences on 𝜽 , the length-𝑝 column vector of mean parameters
in the marginal structural mean model of interest. For notational convenience, let D be the set of
DTRs embedded in the SMART under study; for instance, in design II,
D =
{
(𝑎1, 𝑎2R, 𝑎2NR) : 𝑎1 ∈ {−1, 1} , 𝑎2R = 0, 𝑎2NR ∈ {−1, 1}
}
.
We will write 𝒀 (𝑑) := 𝒀 (𝑎1,𝑎2R,𝑎2NR) .
Let𝑊 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) be a weight associated with participant 𝑖 and DTR 𝑑 ∈ D defined as
𝑊 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) =
𝐼 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2)
𝑃(𝐴𝑖,1 = 𝑎1)𝑃(𝐴𝑖,2 = 𝑎2 | 𝐴𝑖,1 = 𝑎1, 𝑅𝑖)
, (2.5)
where 𝐼 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) is an indicator of whether participant 𝑖 is consistent with DTR 𝑑. The
form of 𝐼 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) depends on the particular SMART design under study; for each of the
designs in figure 1.1, these expressions are shown in table 2.1.
We use 𝑊 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) to account for the facts that, in some SMARTs (e.g., designs II
and III) there is known imbalance in the proportion of responders and non-responders consistentwith
eachDTR, and that that some (or all) participants are consistent withmore than one embeddedDTR.
This imbalance can be corrected using inverse-probability weighting (Nahum-Shani et al. 2012a;
Cole and Hernán 2008; Chakraborty and Moodie 2013).
In design II, for example, only non-responders to first-stage treatment are re-randomized; if
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Table 2.1: Design-specific indicators for consistency with a given DTR 𝑑 ∈ D.
Design 𝐼 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2)
I 1{𝐴𝑖,1=𝑎1}
(










𝑅𝑖 + 1{𝐴𝑖,2=𝑎2NR} (1 − 𝑅𝑖)
))
all randomizations are with probability 0.5,𝑊 (1,0,1) (1, 1, 0) = (.5×1)−1 = 2 and𝑊 (1,0,1) (1, 0, 1) =
(.5 × .5)−1 = 4. Note that in design I, all participants are re-randomized; hence, all participants
receive a weight of 4. The analyst may freely substitute𝑊 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) = 𝐼 (𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) in
this case.
Define 𝑫 (𝑑) (𝑿𝑖) ∈ R𝑇×𝑝 to be the Jacobian of 𝝁(𝑑) (𝑿𝑖; 𝜽) with respect to 𝜽; i.e., 𝑫 (𝑑) (𝑿𝑖) =
𝜕𝝁(𝑑) (𝑿𝑖; 𝜽)/𝜕𝜽𝑇 . Let 𝑽 (𝑑) (𝑿𝑖; 𝝉) ∈ R𝑇×𝑇 be a working covariance matrix for 𝒀 (𝑑) , conditional
on baseline covariates 𝑿, under DTR 𝑑 ∈ D. Here, 𝝉 = (𝝈>, 𝝆>)> is a vector of parameters
indexing variance (𝝈) and correlation (𝝆) components of the working covariance structure. We













· 𝑫 (𝑑) (𝑿𝑖)>𝑽 (𝑑) (𝑿𝑖; 𝝉)−1
(
𝒀 𝑖 − 𝝁(𝑑) (𝑿𝑖; 𝜽)
)]
. (2.6)
We call the solution to equation (2.6) ?̂?𝑛, and investigate its asymptotic properties in the following
propositions; see appendix B for proofs.
Proposition 2.1. Suppose 𝝁(𝑑) (𝑿; 𝜽) is a correctly-specified model for E
[
𝒀 (𝑑) | 𝑿
]
. Then 𝜽𝑛 is




















𝑫 (𝑑) (𝑿𝑖)>𝑽 (𝑑) (𝑿𝑖; 𝝉)−1𝑫 (𝑑) (𝑿𝑖)












𝑫 (𝑑) (𝑿𝑖)>𝑽 (𝑑) (𝑿𝑖; 𝝉)−1
(





with 𝒁⊗2 = 𝒁𝒁>.
Note that ?̂?𝑛 is consistent for 𝜽 regardless of the chosen structure of 𝑽 (𝑑) (𝑿; 𝝉); however, we
conjecture that choices of𝑽 (𝑑) (𝑿; 𝝉) closer to the true covariance matrixVar(𝒀 (𝑑)) will yield more
efficient estimates.
2.2.3 Estimation of the Working Covariance Matrix
In general, for an embedded DTR 𝑑 ∈ D, 𝑽 (𝑑) (𝑿𝑖;𝝈, 𝝆) takes the form
𝑽 (𝑑) (𝑿𝑖;𝝈, 𝝆) = 𝑺 (𝝈)1/2 𝑹(𝑑) (𝝆)𝑺 (𝝈)1/2 , (2.9)
where 𝑺(𝝈)1/2 ∈ R𝑇×𝑇 is a diagonal matrix with diagonal entries 𝜎1, . . . , 𝜎𝑇 , and 𝑹(𝑑) (𝝆) is a
working correlation matrix for𝒀 (𝑑) . Note that this notation allows for different working correlation
structures for each DTR, as well as non-constant variances in the repeated-measures outcome.
We propose the following procedure to estimate 𝑽 (𝑑) (𝑿𝑖; 𝝉), where 𝝉 = (𝝈>, 𝝆>)>. First,
estimate 𝜽 by solving equation (2.6) using the 𝑇 × 𝑇 identity matrix as 𝑽 (𝑑) (𝑿𝑖; 𝝉) for all 𝑑 ∈ D.








(𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) (𝑌𝑖,𝑡 − `(𝑑)𝑡 (𝑿𝑖; ?̂? (0)))2∑𝑛
𝑖=1𝑊
(𝑑) (𝐴𝑖,1, 𝑅𝑖, 𝐴𝑖,2) − 𝑝 , (2.10)
where 𝑝 is the dimension of 𝜽 . If the scientist believes that this variance is constant over time
for each DTR, the estimate in equation (2.10) can be averaged over time; one can also average
over DTR if one believes the variance is constant across all embedded DTRs. Estimators for 𝝆(𝑑)
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Table 2.2: Correlation estimators for selectedworking correlation structures. The top entries define estimators under the
assumption of constant within-person variance over time; the bottom entries allow for time-varying variances. 𝑑 ∈ D is
an embedded DTR,𝑊 (𝑑)
𝑖
is shorthand for𝑊 (𝑑) (𝐴𝑖,1, 𝑅𝑖 , 𝐴𝑖,2), and 𝑒 (𝑑)𝑖,𝑡 (?̂?) is the estimated residual 𝑌𝑖,𝑡 − ˆ̀
(𝑑)
𝑡 (𝑿𝑖; ?̂?).
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vary with choice of correlation structure 𝑹(𝑑) (𝝆); we present estimators for selected structures in
table 2.2 which assume variance is constant in time.
We estimate𝑽 (𝑑) (𝑿𝑖; 𝝉) by plugging appropriately-pooled estimates of𝝈 from equation (2.10)
and of 𝝆 from table 2.2 into equation (2.9). The form of 𝑹(𝑑) (𝝆) can be chosen according to existing
domain knowledge for primary analyses; secondary analyses might use exploratory methods to
discover an appropriate working correlation structure.
2.2.4 Iterated Estimation Procedure
After estimating 𝑽 (𝑑) (𝑿𝑖; 𝝉), we again solve equation (2.6), this time using ?̂?
(𝑑) (𝑿𝑖; ?̂?(𝑑)) =
𝑺(?̂? (𝑑))1/2𝑹(𝑑) ( ?̂?(𝑑))𝑺(?̂? (𝑑))1/2 as the working covariance matrix. This yields a “one-step” esti-
mator of 𝜽 , which we denote by ?̂? (1) . This process can be further iterated, as suggested by Liang
and Zeger (1986); that is, we can use ?̂? (1) in equation (2.10) to obtain a new estimate for the
working covariance structure, and so on until convergence. We call the final estimate of the model
parameters ?̂? .
Work by Lipsitz et al. (2017) indicates that the one-step estimator is asymptotically equivalent
to the “fully-iterated” estimator and is much less computationally intensive when the number
of repeated measures is large. Anecdotally, we have found in reasonable simulation models for
SMARTs with five or fewer measurement occasions that fully-iterated estimates tend to converge
19
in 𝐿2-norm within a tolerance of 10−8 after about six iterations and do not represent significant
computational burden.
2.3 Sample Size Formulae for End-of-Study Comparisons of
Embedded DTRs in Two-Stage SMARTs
The estimation procedure presented in section 2.2 is general. The marginal structural mean model
𝝁(𝑑) (𝑿𝑖; 𝜽) can take any form appropriate for the SMART under analysis, data can be observed
at any number of measurement occasions, and the working covariance matrix can have arbitrary
structure (Lu et al. 2016).
We now develop sample size formulae for SMARTs in which the primary aim is to compare
the mean end-of-study outcomes for two embedded DTRs that recommend different first-stage
treatments and which satisfy certain design constraints. For a variety of reasons, there is an
interest in collecting repeated-measures outcomes even in settings in which the primary aim is
an end-of-study comparison. Because repeated measurements within the same person are often
positively correlated, analyses which leverage this information can be more efficient than those
which do not (Cook and Ware 1983). This can be especially beneficial in situations with small
signal-to-noise ratios. Furthermore, longitudinal data allows investigators to examine trajectories
over time, regardless of the primary comparison. This can help tell a fuller story about change over
time.
For the sample size methods developed here, we restrict our focus to two-stage SMARTs
in which the outcome is observed at three equally-spaced measurement occasions — baseline,
just prior to assessment of the tailoring variable and subsequent randomization, and at the end
of the study — and in which all randomizations occur with probability 0.5. For simplicity, we
ignore baseline covariates; this is a conservative assumption, since it will inflate the variance of
the estimates from equation (2.6). Additionally, we consider a saturated, piecewise-linear mean
structure 𝝁(𝑑) (𝜽) similar to models (2.1) to (2.3).
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Let 𝒄 be some contrast vector so that the primary aim null hypothesis takes the form
𝐻0 : 𝒄>𝜽 = 0,
which we will test against an alternative of the form 𝐻1: 𝒄>𝜽 = Δ. To compare mean end-of-study
outcomes between two embedded DTRs which recommend different first-stage treatments, the












for some choice of 𝑎2R, 𝑎′2R, 𝑎2NR, and 𝑎
′
2NR. For example, to test equality of mean end-of-study
outcomes for DTRs (1, 0, 1) and (-1, 0, -1) in design II under model (2.1) (assuming no 𝑿,{
𝑡 𝑗
}
= {0, 1, 2}, 𝑡∗ = 1), the estimand (2.11) can be written as the linear combination 𝒄>𝜷, where
𝒄> = (0, 0, 2, 0, 2, 2, 0).
Because we are interested in a single contrast (i.e., 𝒄 is a vector, not a matrix) we employ a















the test statistic follows a standard normal distribution.






where 𝜎 = Var(𝑌 (𝑑)
𝑗
) for arbitrary 𝑗 (see working assumption A2.2 below).
The sample size formulae will require the response rate 𝑃(𝑅(𝑎1) = 1) = 𝑟𝑎1 , where 𝑅(𝑎1) is
the potential response to first-stage treatment 𝑎1. In order to simplify the form of 𝜎𝑐 and obtain
tractable, intepretable sample size formulae, we make the following working assumptions:
A2.1 Constrained conditional covariance matrices for DTRs under comparison.
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(a) The variability of 𝑌 (𝑑)𝑡 around the DTR mean `
(𝑑)
𝑡 (𝜽) among responders and non-






















for all 𝑡 > 𝑡∗ and DTRs 𝑑 ∈ D under study.
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= 0.
for DTRs 𝑑 ∈ D under study.
(c) The covariance between the end-of-study measurement and the measurements prior to


















(𝑎 (𝑑)1 ) = 0
)
for DTRs 𝑑 ∈ D under study and 𝑡 = 0, 1. An additional, related assumption is given in
appendix B.2.
A2.2 Exchangeable marginal covariance structure. The marginal variance of 𝒀 (𝑑) is constant











for all 𝑑 ∈ D.
These working assumptions may be seen as overly simplifying; however, we will see in sec-
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tions 2.4.2 and 2.5 that formula (2.13) is robust to moderate violations of working assumption A2.1
and that inputs to the formula can be adjusted in a way to accommodate violations of working
assumption A2.2. A working assumption similar to A2.1(a) is commonly made in developing
sample-size formulae for SMARTs using end-of-study outcomes (Oetting et al. 2011; Kidwell
et al. 2018; NeCamp, Kilbourne, and Almirall 2017). Working assumptions A2.1(b) and A2.1(c),
as well as A2.2, are necessary for the extension to the setting of a repeated-measures outcome with
our proposed estimator.
Working assumption A2.1 arises specifically as a consequence of unequal weights in equa-
tion (2.6) (i.e., when there exists imbalance between responders and non-responders, by design);
therefore, the assumption is not necessary in design I, and can be relaxed to apply to only the two
DTRs in which non-responders are re-randomized in design III. Furthermore, working assump-
tion A2.2 cannot be satisfied in design I if all eight embedded DTRs have unique means.
Under working assumptions A2.1 and A2.2, the minimum-required sample size to detect a







· (1 − 𝜌2) · DE, (2.13)
where DE is a SMART-specific “design effect” for an end-of-study comparison (see table 2.3).
Note that the first term in formula (2.13) is the typical sample size formula for a traditional two-arm
randomized trial with a continuous end-of-study outcome and equal randomization probability.
The middle term is due to the within-person correlation in the outcome, and is identical to the
corresponding correction term for GEE analyses sized to detect a group-by-time interaction when
there is no baseline group effect (see, e.g, Fitzmaurice, Laird, and Ware 2011, ch. 20)
The sample size formula presented in formula (2.13) is conservative. It becomes more
conservative as 𝜌 approaches (1 +
√
5)/2 ≈ 0.62. A sharper formula is available in appendix B.2;
however, we emphasize formula (2.13) as it is more immediately intepretable.
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Table 2.3: SMART-specific design effects for sample size formula 2.13. 𝑟𝑎1 = 𝑃(𝑅 (𝑎1) = 1) is the response rate to
first-stage treatment 𝑎1. The conservative design effect maximizes the sample size requirement by assuming 𝑟𝑎1 = 0.
Design Design effect Conservative design effect
I 2 2
II 12 (2 − 𝑟1) +
1
2 (2 − 𝑟−1) 2




We conducted a variety of simulations to assess the performance of sample size formula (2.13).
We are interested in the empirical power for a comparison of the DTR which recommends only
treatments indicated by 1 and the DTR which recommends only treatments indicated by −1 when
the study is sized to detect an effect size of 𝛿. In ENGAGE, this might correspond to a comparison
of mean end-of-study outcomes under the DTR which recommends MI-IOP in the first stage, no
further contact for engagers, and MI-PC in the second stage for continued non-engagers versus the
mean end-of-study outcomes under the regimen which recommends MI-PC in the first-stage, then
no further contact for both engagers and non-engagers.
We consider four types of scenarios: first, when no assumptions are violated; second, when
each of working assumptions A2.1(a) to A2.1(c) are violated; finally, when the working correlation
structure is misspecified, in violation of working assumption A2.2. In each scenario, sample sizes
are computed based on nominal power 1 − 𝛾 = 0.8 and two-sided type-I error 𝛼 = 0.05.
We believe sample sizes from formula (2.13) will be slightly conservative when all assump-
tions are satisfied, as formula (2.13) is an interpretable upper bound on a sharper formula given
in appendix B.2 and the supplement. For design I, we do not expect power to be affected by
violations of working assumption A2.1, as the assumption arises as a consequence of over- or
under-representation of responders and non-responders consistent with a particular DTR (see
appendix B.2). Since there is no such imbalance in design I, working assumption A2.1 is not appli-
cable. Similarly, in design III, only non-responders to one first-stage treatment are re-randomized,
so we expect that empirical power will decrease slightly, but not seriously, when violating working
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assumption A2.1. We expect empirical power to suffer most severely when violating this working
assumption in design II.
We further conjecture that scenarios in which the true within-person correlation structure of
𝒀 (𝑑) is autoregressive, sample sizes from formula (2.13) will be very anti-conservative. Under
an AR(1) correlation structure, less information about the end-of-study outcome is provided by
the baseline measure than would be under an exchangeable correlation structure. Since, by using
formula (2.13), we have assumed more information is available from earlier measurements than
is actually the case, we will be underpowered. Similarly, we expect over-estimation of 𝜌 in
formula (2.13) to lead to anti-conservative sample sizes.
2.4.1 Data Generative Process
For each simulation, the true marginal mean model is as in models (2.1) to (2.3) for designs I
to III, respectively. We do not include baseline covariates 𝑿; this is a conservative approach, as
we believe that adjustment for prognostic covariates typically will increase power: see, eg., Kahan
et al. (2014). Estimates of marginal means from ENGAGE were used to inform a reasonable range
of “true” means from which to simulate, though the scenarios presented here are not designed to
mimic ENGAGE exactly. All simulations take 𝑇 = 3 and values of 𝜷 and 𝜎 are chosen to achieve
𝛿 = 0.3 or 𝛿 = 0.5 (“small” and “moderate” effect sizes, respectively).
Data were generated according to a conditional mean model which, when averaged over
response, yields the marginal model of interest. Potential outcomes 𝑌 (𝑑)
𝑖, 𝑗
were simulated from
appropriately-parameterized normal distributions (see section 4.1 for details); data were “observed”
by selecting the potential outcome corresponding to treatment assignment as generated from a
Bernoulli(0.5) distribution.
We consider three mechanisms for generating response status. In the first, “𝑅⊥ ”, response
is generated from a Bernoulli(𝑟𝑎1) distribution, where 𝑟𝑎1 = 𝑃(𝑅(𝑎1) = 1), independently of all
previously-observed data. In the second and third scenarios (“𝑅+” and “𝑅−”, respectively), response
status is still generated from a Bernoulli distribution, but each individual is assigned a beta-
25
distributed probability of response correlated with their observed value of 𝑌1. These correlations
are either positive or negative, depending on the responsemodel. This is intended tomimic different
coding choices for 𝒀 , in the sense of responders tending to have higher or lower values of 𝑌1 than
non-responders.
For each simulation scenario, we compute upper and lower bounds on allowable values of
Var(𝑌 (𝑑)2 | 𝑅
(𝑎 (𝑑)1 ) = 1), beyond which it is not possible to either achieve the desired marginal
variance, or which induces violation of working assumption A2.1(a). The results shown in the
corresponding column of table 2.4 were generated when responders’ variances were set to 75% of
the lower bound beyond which the fixed marginal variance forces E[(𝑌 (𝑑)𝑡 − `
(𝑑)




Violation of working assumption A2.1(b) was induced by defining response status as
𝑅(𝑎
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distribution, respectively. This ensures control on response probability while also inducing large








1) > Cor(𝑌 (𝑑)𝑡 , 𝑌
(𝑑)
2 | 𝑅 = 0) while keeping respective variances fixed. In our generative model,
it was difficult to exert precise control over these quantities when response was related to prior
outcomes; as such, these violations were induced under the 𝑅⊥ response model.
There exist natural constraints on howmuch larger thanCov(𝑌 (𝑑)𝑡 , 𝑌
(𝑑)
2 | 𝑅 = 0) the responders’
covariance can be while ensuring that (1) all conditional covariance matrices are positive definite
and (2) Cov(𝑌 (𝑑)𝑡 , 𝑌
(𝑑)
2 | 𝑅
(𝑎 (𝑑)1 ) = 0) ≥ 0 for 𝑡 = 0, 1. These constraints vary with 𝜌. We choose
Cor(𝑌 (𝑑)𝑡 , 𝑌
(𝑑)
2 | 𝑅
(𝑎 (𝑑)1 ) = 1) such that Cov(𝑌 (𝑑)𝑡 , 𝑌
(𝑑)
2 | 𝑅
(𝑎 (𝑑)1 ) = 1) is the midpoint between the
minimum covariance for which the assumption is violated and the maximum covariance allowed
by the aforementioned constraints.
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2.4.2 Simulation Results
Simulation results based on 3,000 simulated data sets are compiled in table 2.4. We find that sample
size formula (2.13) performs as expected when all assumptions are satisfied. Empirical power is
not significantly less than the target power of 0.8, per a one-sided binomial test with level 0.05.
The sample size is, as expected, often conservative, particularly when within-person correlation is
high.
Table 2.4: Sample sizes and empirical power results for an end-of-study comparison of the DTR recommending only
treatments indexed by 1 and that which recommends only treatments indicated by −1. 𝛿 is the true standardized effect
size as defined in equation (2.12), 𝑟 is the common probability of response to first-stage treatment, and 𝜌 is the true
exchangeable within-person correlation. 𝑛 is computed using formula (2.13) with 𝛼 = 0.05 and 𝛾 = 0.2. 𝑅⊥ refers to a
generative model in which response status is independent of all prior outcomes; 𝑅+ and 𝑅− refer to generative models
in which response is positively or negatively correlated with 𝑌1, respectively. All violation scenarios assume the 𝑅+
generative model, except working assumption A2.1(c). Results are the proportion of 3000 Monte Carlo simulations in
which we reject 𝐻0 : 𝒄>𝜽 = 0 at the 5% level.
Empirical power
A2.1 and A2.2 satisfied Violation of A2.1 Violation of A2.2
Design 𝛿 𝑟 𝜌 𝑛 𝑅⊥ 𝑅+ 𝑅− A2.1(a) A2.1(b) A2.1(c) True AR(1)
I 0.3 0.4 0.0 698 0.798 0.807 0.803 0.798 0.796 ‡ ‡
0.3 635 0.819 0.817 0.800 0.820 0.804 0.815 0.780∗
0.6 447 0.815 0.862 0.773∗ 0.865 0.817 0.827 0.728∗
0.8 252 0.835 0.925 0.733∗ † † 0.840 0.721∗
0.6 0.0 698 0.796 0.799 0.806 0.800 0.791 ‡ ‡
0.3 635 0.808 0.813 0.792 0.824 0.805 0.807 0.775∗
0.6 447 0.833 0.856 0.798 0.859 0.831 0.838 0.727∗
0.8 252 0.827 0.901 0.758∗ † † 0.835 †
0.5 0.4 0.0 252 0.799 0.801 0.798 0.798 0.801 ‡ ‡
0.3 229 0.813 0.815 0.797 0.814 0.811 0.814 0.771∗
0.6 161 0.824 0.872 0.789 0.868 0.833 0.843 0.742∗
0.8 91 0.843 0.931 0.734∗§ 0.926 † 0.839§ 0.725∗
0.6 0.0 252 0.796 0.797 0.810 0.792 0.802 ‡ ‡
0.3 229 0.817 0.815 0.808 0.811 0.823 0.823 0.771∗
0.6 161 0.838 0.859 0.790 0.861 0.832 0.837 0.749∗
0.8 91 0.835§ 0.896 0.765∗§ 0.896 † 0.859 †
II 0.3 0.4 0.0 559 0.801 0.801 0.808 0.778∗ 0.803 ‡ ‡
0.3 508 0.804 0.813 0.831 0.800 0.797 0.798 0.795
0.6 358 0.817 0.819 0.834 0.807 0.759∗ 0.788 0.811
0.8 201 0.836 0.814 0.836 0.809 † 0.792 0.806
0.6 0.0 489 0.804 0.796 0.793 0.736∗ 0.810 ‡ ‡
0.3 445 0.797 0.804 0.818 0.758∗ 0.795 0.780∗ 0.804
0.6 313 0.824 0.831 0.844 0.793 0.752∗ 0.770∗ 0.824
0.8 176 0.845 † † 0.754∗ † 0.776∗ 0.842




A2.1 and A2.2 satisfied Violation of A2.1 Violation of A2.2
Design 𝛿 𝑟 𝜌 𝑛 𝑅⊥ 𝑅+ 𝑅− A2.1(a) A2.1(b) A2.1(c) True AR(1)
0.3 183 0.813 0.800 0.819 0.790 0.813 0.796 0.803
0.6 129 0.814 0.828 0.833 0.810 0.763∗ 0.799 0.815
0.8 73 0.839 0.841 0.852 0.829 † 0.795 0.804
0.6 0.0 176 0.807 0.799 0.796 0.733∗ 0.808 ‡ ‡
0.3 160 0.816 0.815 0.821 0.767∗ 0.808 0.802 0.812
0.6 113 0.829 0.830 0.837 0.792 0.765∗ 0.770∗ 0.817
0.8 64 0.845§ † † 0.783∗§ † 0.789§ †
III 0.3 0.4 0.0 454 0.806 0.813 0.806 0.782∗ 0.794 ‡ ‡
0.3 413 0.815 0.809 0.814 0.789 0.800 0.800 0.775∗
0.6 291 0.821 0.811 0.818 0.794 0.783∗ 0.787∗ 0.687∗
0.8 164 0.824 0.812 0.839 0.812 † 0.802 0.637∗
0.6 0.0 419 0.813 0.814 0.817 0.781∗ 0.769∗ ‡ ‡
0.3 381 0.823 0.812 0.808 0.776∗ 0.791 0.795 0.771∗
0.6 268 0.823 0.817 0.844 0.807 0.750∗ 0.754∗ 0.709∗
0.8 151 0.820 † † 0.803 † 0.784∗ †
0.5 0.4 0.0 164 0.808 0.804 0.795 0.776∗ 0.802 ‡ ‡
0.3 149 0.822 0.815 0.827 0.811 0.791 0.805 0.789
0.6 105 0.811 0.810 0.812 0.810 0.798 0.785∗ 0.698∗
0.8 59 0.838 † 0.823 0.845 † 0.817§ 0.684∗
0.6 0.0 151 0.798 0.809 0.803 0.778∗ 0.772∗ ‡ ‡
0.3 138 0.812 0.809 0.814 0.800 0.782∗ 0.799 0.778∗
0.6 97 0.803§ 0.812 0.826§ 0.826§ 0.762∗ 0.774∗§ 0.705∗§
0.8 55 0.826§ † † 0.837§ † 0.797§ †
∗ Statistically significantly less than 0.8 at the 5% level.
† Our data generative model could not accommodate this scenario.
‡ Violation of this working assumption is not applicable when 𝜌 = 0.
§ Fewer than 3000 simulations generated data in which all treatment sequences were observed.
There may be some concern that, for high within-person correlation, formula (2.13) is overly
conservative; should this concern arise, we recommend use of the sharper formulae presented in the
supplement. The difference between the sharper formulae and formula (2.13) is maximized when
𝜌 = (1+
√
5)/2 ≈ 0.62, so we expect to see the largest differences in power between formula (2.13)
and the sharp formula when we set 𝜌 = 0.6.
When all working assumptions are satisfied, we see that empirical power for 𝑅+ and 𝑅−
scenarios are similar or slightly higher than under the 𝑅⊥ model. In general, there do not appear to
be practical differences in empirical power between the response models.
As conjectured, violating working assumption A2.1(a) does not impact empirical power in
design I (compare the results to column “𝑅+”). For design II, empirical power is consistently
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less than the nominal value when working assumption A2.1(a) is violated. However, while the
empirical power is often statistically significantly less than 0.8, for practical purposes the loss of
power is relatively small. For design III, we notice small reductions in power relative to scenarios
in which both working assumptions A2.1 and A2.2 are satisfied, though the conservative nature of
formula (2.13) appears to protect against more severe loss of power. This suggests that our sample
size formula is moderately robust to reasonable violations of A2.1(a).
For small 𝜌, we see nomeaningful change in empirical power when violating working assump-
tion A2.1(b). However, as 𝜌 increases, this also leads to increased correlation between response
and the other products of first-stage residuals, which increases the severity of the violation. For
𝜌 = 0.6, we see noticeable, but not extreme, departures from nominal power. When 𝜌 = 0.8,
our generative model was not able to violate working assumption A2.1(b) without also violating
working assumption A2.1(a); as such, we omit those results.
Interestingly, as can be seen in the supplement, defining non-response as in equation (2.14)
(i.e., replacing 𝑅(𝑎1) with 1−𝑅(𝑎1)) leads to higher-than-nominal power. When there exists negative
correlation between response and products of squared first-stage residuals, the form of 𝜎2𝑐 derived
in appendix B.2 is more conservative, leading to increased power.
Simulation results show that our sample size formula is quite robust to violations of working
assumption A2.1(c) for low-to-moderate within-person correlations; at high correlations, the empir-
ical power is statistically significantly less than 0.8. However, as with working assumption A2.1(a),
the practical reduction in power is relatively small.
The final column of table 2.4 suggests that formula (2.13) is highly sensitive to violations of
working assumption A2.2 in regards to the true correlation structure. In particular, when the true
correlation structure is not exchangeable with correlation 𝜌 and is instead AR(1) with correlation
𝜌, empirical power is substantially lower than the target of 0.8, particularly as 𝜌 increases. This
is unsurprising: as our assumed exchangeable 𝜌 increases, the difference between the assumed
and actual correlation between the end-of-study measurement and earlier measurements increases,
leading to more severe loss of power.
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Figure 2.1: Empirical power under misspecified within-person correlation. Simulated power is plotted against the
difference between the true within-person correlation 𝜌 and hypothesized correlation 𝜌guess used to compute sample
size. Results are shown for design II with a hypothesized response rate of 0.4, and sample size was chosen to detect
standardized effect size 𝛿 = 0.3 for the comparison of DTRs (1, 0, 1) and (-1, 0, -1). Each point is based on 3000
simulations with target power 0.8 and significance level 0.05. Results are similar for designs I and III and different
values of 𝛿 and 𝑟.
Note that when within-person correlation is high, sample size becomes rather small. Since the
method presented here is based on asymptotic normality, we caution the reader that small sample
sizes (e.g., 𝑛 < 100) provided by formula (2.13) may be quite sensitive to violation of the working
assumptions.
In figure 2.1, we examine the effect on empirical power of misspecifying the within-person
correlation. Analytically, we see from formula (2.13) that if the assumed 𝜌 is smaller than the
true within-person correlation, the sample size will be conservative. On the other hand, when
the assumed 𝜌 in formula (2.13) is larger than the true correlation, the sample size will be anti-
conservative. Figure 2.1 shows plots of empirical power against the difference between the assumed
within-person correlation 𝜌guess and the true 𝜌. For small 𝜌guess, formula (2.13) appears to be quite
robust to misspecification of 𝜌; however, as 𝜌guess increases, the formula becomes highly sensitive
to such a violation of working assumption A2.2. This is supported analytically, since formula (2.13)
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is a function of 𝜌2guess.
2.5 Discussion
Wehave derived sample size formulae for SMARTdesigns inwhich the primary aim is a comparison
of two embedded DTRs that begin with different first-stage treatments on a continuous, longitudinal
outcome observed at three measurement occasions. We derived the formulae for three common
SMART designs.
The sample size formula is the product of three components: (1) the formula for the minimum
sample size for the comparison of two means in a standard two-arm trial (see, e.g., Friedman,
Furberg, and DeMets (2010) page 147), (2) a deflation factor of 1 − 𝜌2 that accounts for the use of
a longitudinal outcome, and (3) a SMART-specific “design effect”, an inflation factor that accounts
for the SMART design.
The SMART design effect can be interpreted as the cost of conducting the SMART relative
to conducting a standard two-arm randomized trial of the two DTRs which comprise the primary
aim. The benefit of conducting a SMART (relative to the standard two-arm randomized trial) is the
ability to answer additional, secondary questions that are useful for constructing effective DTRs.
For example, such questions may focus on one or more of the other pairwise comparisons between
DTRs, on whether the first- and second-stage treatments work synergistically to impact outcomes
(e.g., a test of the null that 𝛽6 = 0 in model (2.1)), or may focus on hypothesis-generating analyses
that seek to estimate more deeply-tailored DTRs (Watkins 1989; Nahum-Shani et al. 2012b; Zhang
et al. 2015).
The formulae are expected to be easy-to-use for both applied statistical workers and clinicians.
Indeed, inputs 𝛼, 𝛾, and Δ are as in the sample size formula for a standard 𝑧-test. Furthermore,
estimates of 𝜌, 𝑟𝑎1 , and 𝜎 are often readily available from the literature or can be estimated using
data from prior studies (e.g., prior randomized trials, or external pilot studies).
We make a number of recommendations concerning the use of the formulae; in particular,
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how best to use the formulae conservatively in the absence of certainty concerning prior estimates
of 𝜌, 𝑟𝑎1 , and/or the structure of the variance of the repeated measures outcome. First, in designs II
and III, if there is uncertainty concerning the response rate (e.g., response rate estimates are based
on data from smaller prior studies), one approach is to err conservatively by assuming a smaller-
than-estimated response rate. In both designs, the most conservative approach is to assume a
response rate of zero.
Second, as in standard randomized trials in which the primary aim is a pre-post comparison,
the required sample size decreases as the hypothesized within-person correlation increases (Zhang,
Cao, and Ahn 2014). Therefore, if the hypothesized 𝜌 is larger than the true 𝜌, the computed
sample size will be anti-conservative, resulting in an under-powered study. Indeed, we see this
in the results of the simulation experiment (see figure 2.1). Here, again, one approach is to err
conservatively towards smaller values of 𝜌.
Finally, working assumption A2.2 (concerning the variance of the repeatedmeasures outcome)
may be seen as overly restrictive in the imposition of an exchangeable correlation structure. For
example, studies with a continuous repeated measures outcome may observe an autoregressive cor-
relation structure. However, the exchangeable working assumption can be employed conservatively
in the following way: if the hypothesized structure is not exchangeable, one approach is to set 𝜌
in formula (2.13) to the smallest plausible value (e.g., the within-person correlation between the
baseline and end-of-study measurements for an autoregressive structure). Because this approach
utilizes a lower bound on the value of the true within-person correlations, it is expected to yield a
larger than needed (more conservative) sample size. Similarly, if the true within-person correlation
is expected to differ by DTR, one approach is to employ the smallest plausible 𝜌. As with the third
recommendation, these recommendations are not unique to SMARTs; indeed, these strategies may
also be used to size standard two-arm randomized trials with repeated measures outcome.
In the case whereVar(𝑌 (𝑑)
𝑗
) varies with time and/or DTR, we conjecture that power will suffer
if a pooled estimate of 𝜎2 is used when the variance decreases with time. To see this, consider that
the standardized effect size 𝛿 defined in equation (2.12) has as a denominator the pooled standard
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deviation of 𝑌 (𝑑)2 across the groups under comparison. Should the estimate of pooled standard
deviation be larger than the true value, the variance of 𝒄>?̂? will increase; since the estimate will be
less efficient than hypothesized, power will be lower than expected. Conversely, we also conjecture
that whenVar(𝑌 (𝑑)
𝑗
) increases with 𝑡, the sample size will be conservative using similar reasoning.
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CHAPTER 3
Balancing Sample Size and Measurement Occasions
in Longitudinal SMARTs
Monetary costs are a key consideration of any study; clinical trials are no exception. Martin
et al. (2017) found that “much of the variability in [trial] costs is related to trial protocol design
choices and factors such as the number of [participants], sites, and visits”. Myers et al. (2019)
discuss costs and challenges associted with recruiting participants for a study of major depressive
disorder in adults with type 2 diabetes mellitus, reporting an average of $1358 spent per patient
recruited. Strategies for recruitment included outreach to physicians, pharmacists, and community
diabetes education programs, as well as direct advertising on Facebook, radio, and television.
Sertkaya et al. (2016) found, in a systematic review of multi-site clinical trials in medical research,
that while per-patient costs represent less than half of the total costs associated with these large
trials, recruitment, retention, and intervention expenditures represent an important component of
trial costs.
Longitudinal between-groups analyses have the advantage of reduced sample size requirements
compared to a cross-sectional analysis due to within-person correlation (Hedeker, Gibbons, and
Waternaux 1999). It therefore stands to reason that sample size requirements can be further reduced
with more frequent measurement of the outcome. There is a broad literature exploring the selection
of sample size and number of measurement occasions in randomized trials. To our knowledge,
however, this problem has not been addressed in the context of a SMART.
Overall and Doyle (1994) provided a variety of sample size formulae for “[ANOVA] tests
of significance in a two-group repeated measurements design”, considering a variety of possible
comparisons with and without adjustment for baseline covariates. They discovered that, for the
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these comparisons, the total number of repeatedmeasurements is less meaningful for power than the
number of individuals enrolled in the study. In particular, at least for ANOVA tests, “the analysis of
simple difference scores at endpoint is blind to the number of intervening repeated measurements”
(Overall and Doyle 1994).
Maxwell (1998) showed that two-arm longitudinal trials in which the outcome is measured
five or more times, sized for a comparison of slopes using ANOVA, yield important sample size
reductions relative to a pretest-posttest design with analyzed via analysis of covariance. This was
confirmed and extended by Arndt et al. (2000), who explored the problem in terms of “precision”;
specifically, the relative contributions of additional sample size versusmoremeasurement occasions
to the standard error of the estimate for mean change over time. The idea of optimizing for the
standard error of estimates is interesting; although, for a fixed effect size, target power, and type-I
error, this can be equivalent to optimizing for power.
Raudenbush and Xiao-Feng (2001) considered this problem in two-level hierarchical models,
representing power for a detecting a treatment effect as a function of study duration, measurement
frequency, and sample size. The authors focused primarily on “group differences in polynomial
change”, modeling individual trajectories as polynomial functions in time. Furthermore, they
conceptualized the effect size as a standardized mean difference in polynomial trend. This is a
useful framework to consider, as linear trends may be overly restrictive.
Zhang and Ahn (2011a) consider tradeoffs between adding participants or measurements in
the context of a test for a group-by-time interaction using a GEE estimator under a cost constraint.
Their results are useful for two-arm randomized trials in which the primary aim is a comparison
of slopes. Further work by the same authors extended the results of Overall and Doyle (1994) by
considering a regression model for time-averaged outcomes across groups (Zhang and Ahn 2011b).
The sample size formula presented in Chapter 2 focuses specifically on SMARTs in which the
longitudinal outcome is measured three times. This allowed us to narrow our focus to a saturated
model, which greatly simplified computations. However, such an approach is overly simplistic.
Consider the ENGAGE trial (Figure 1.2) in which outcomes were collected 4, 8, 12, and 24 weeks
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after the baseline assessment (McKay et al. 2015). We conjectured in Chapter 2 that the three-
timepoint simplification would yield a conservative sample size for designs which measure the
outcome more than three times; here, we investigate that conjecture further.
In this chapter, we extend the method in chapter 2 to accommodate a general number of
measurement occasions, with the goal of investigating relationships between the frequency and
timing of measurements and sample size. We present a more general sample size formula in
section 3.2, then discuss balancing sample size and repeated measurements subject to monetary
considerations in section 3.3 .We introduce a simple cost function to describe per-participant
expenditures like recruitment andmeasurement costs, and explore how to allocate resources between
sample size and number of measurement occasions to both minimize cost and achieve a desired
target power. We implement this optimization in an R package, described in chapter 4. Our primary
contribution is a reframing of conversations about sample size between clinicians and statisticians
by accounting for budget considerations in the design stages of the trial, discussed in detail in
section 3.4
3.1 Modeling and Estimation
As in section 2.3, we wish to develop sample size formulae for longitudinal SMARTs in which the
primary aim is the end-of-study comparison of two embedded DTRs which recommend different
first-stage treatments. As before, we consider piecewise-linear models which respect the sequential
randomization in a SMART, as in models (2.1) to (2.3). With three measurement occasions, these
models are fully saturated: the model simply estimates 𝑛DTR + 3 means, where 𝑛DTR is the number
of dynamic treatment regimens embedded in the SMART.
Consider a SMART in which the outcome is measured at 𝑇 occasions 𝑡1 < 𝑡2 < · · · < 𝑡𝑇 .
Define 𝑡∗ as the time of the last measurement prior to re-randomization, 𝑇1 as the number of
measurements in the first stage, from baseline (𝑡1) through 𝑡∗ := 𝑡𝑇1 , and 𝑇2 as the number of
measurements after 𝑡∗ (i.e., in the second stage of the SMART), such that 𝑇1 + 𝑇2 = 𝑇 .
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Figure 3.1: Depiction of clocks for time in the first and second stages of a longitudinal SMART. The dotted line labeled
Stage 1 shows 𝑢1 and the dashed line labeled Stage 2 shows 𝑢2.





(𝜷) = 𝛽0 + 1{𝑡 𝑗≤𝑡∗}
(




𝑡∗𝛽1 + 𝑡∗𝛽2𝑎1 + 𝛽3(𝑡 𝑗 − 𝑡∗) + 𝛽4(𝑡 𝑗 − 𝑡∗)𝑎1






is a marginal structural mean model for E[𝑌 (𝑑)
𝑗
], the expected value of the outcome 𝑌
at time 𝑡 𝑗 had an individual been treated according to DTR 𝑑 ∈ D.
It will be helpful to consider the notion of separate “clocks” for each stage. Define 𝑢1 𝑗 =
min
(
𝑡 𝑗 , 𝑡
∗) and 𝑢2 𝑗 = max (𝑡 𝑗 − 𝑡∗, 0) . 𝑢1 𝑗 is the clock for the first stage of the trial, starting at
𝑡1 and continuing until 𝑡∗, at which point it remains 𝑡∗ for the remainder of the trial time. The
second-stage clock, 𝑢2 𝑗 , is zero through the first stage, then counts time since 𝑡∗ through the end of
the trial. A visual depiction of the clocks is given in figure 3.1.
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(𝜷) = 𝛽0 + 𝛽1𝑢1 𝑗 + 𝛽2𝑢1 𝑗𝑎 (𝑑)1 + 𝛽3𝑢2 𝑗 + 𝛽4𝑢2 𝑗𝑎
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(𝜷) = 𝛽0 + 𝛽1𝑢1 𝑗 + 𝛽2𝑢1 𝑗𝑎 (𝑑)1 + 𝛽3𝑢2 𝑗 + 𝛽4𝑢2 𝑗𝑎
(𝑑)
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+ 𝛽5𝑢2 𝑗𝑎 (𝑑)2R + 𝛽6𝑢2 𝑗𝑎
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(𝜷) = 𝛽0 + 𝛽1𝑢1 𝑗 + 𝛽2𝑢1 𝑗𝑎 (𝑑)1 + 𝛽3𝑢2 𝑗 + 𝛽4𝑢2 𝑗𝑎
(𝑑)
1 + 𝛽5𝑢2 𝑗1{𝑎 (𝑑)1 =1}𝑎 (𝑑)2NR, (3.3)
respectively.



















𝒀 𝑖 − 𝝁(𝑑) (𝜷)
)]
. (2.6 revisited)
The (robust or sandwich) variance of ?̂? is given by 𝑩−1𝑴𝑩−1, where 𝑩 and 𝑴 are as defined in
equations (2.7) and (2.8), respectively. Following proposition 2.1, the solution ?̂? to the estimating
equations is consistent for 𝜷∗, the true, causal parameter vector, provided that the model is correctly











3.2 Sample Size Formulae for End of Study Comparisons
We remain interested in an end-of-study comparison of two embedded DTRs which recommend
different first-stage treatments. Using the potential outcomes notation developed in section 2.1, the
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Notice that the contrast involves the stage-1 clock 𝑢1, despite the estimand being a comparison
of mean end-of-study outcomes. This is a consequence of the DTRs under study recommending
different first-stage treatments. It highlights the fact that our regression-based approach to estimating





= 𝑩−1𝑴𝑩−1, the 2𝑢1𝑇 component will “pick up” variability from the first-stage of the
study. We will see that this is important for understanding the behavior of the sample size formula
in section 3.3.
As in chapter 2, we wish to size the SMART for a test of the null hypothesis
H0 : 𝒄>𝜷 = 0






developing a useful sample size formula depends on obtaining a tractable expression for
𝒄>𝑩−1𝑴𝑩−1𝒄, the variance of the contrast 𝒄> ?̂?.
We make the following working assumptions to aid in the development of the formulae:
A3.1 Constrained conditional variability.
(a) For all DTRs 𝑑 ∈ D, the element-wise difference between the matrix of variability of
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responders’ outcomes around the DTR mean and the marginal covariance matrix of the






















≥ 𝐵 implies that 𝐴−𝐵 is positive semi-definite; 𝐿 refers to the Loewner partial
order (see appendix B.3).
(b) For all DTRs 𝑑 ∈ D, the element-wise difference between the marginal covariance
matrix of the outcome, inflated by response probability, and the matrix of variability of































𝒀 (𝑑) | 𝑅(𝑎
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𝝁(𝑑) − 𝝁(𝑑 ′)
)>
is “small”.
A3.3 Equal spacing. Measurement occasions are equally-spaced in both stages, which are of fixed




𝑇1−1 𝑗 = 1, 2, . . . , 𝑇1
𝑡∗ + (𝑡𝑇 − 𝑡∗) · 𝑗−𝑇1𝑇2 𝑗 = 𝑇1 + 1, . . . , 𝑇
.
We continue to make working assumption A2.2, which assumes an exchangeable within-person
correlation structure marginal over response status, and constant marginal variances across time
and DTR. We also restrict 𝜌 ∈ [0, 1].
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Working assumption A3.1 is a generalization of working assumption A2.1. Indeed, A2.1 is
an interpretable way to describe A3.1 in the three timepoint setting. Unfortunately, A3.1 is not
particularly interpretable and may be difficult to assess intuitively. It is currently unclear what
“small” means in working assumption A3.2; however, the idea is that the mean outcomes for
responders are relatively close to marginal mean trajectories.
We claim that working assumption A3.3 is a realistic simplification. In appendix C, we inves-




without equally-spaced measurements and show that, generally,
the trends discussed below are maintained, though the function is noticeably less smooth. Finally,
under working assumption A2.2, a negative within-person correlation would imply that individuals
experience noticeable fluctuation in the outcome over time, which is typically not the case in be-
havioral science settings. In appendix C, we present a more general version of equation (3.7) which
does not require working assumption A3.3 and is implemented in software described in chapter 4.
Under working assumptions A3.1 and A2.2, the minimum-required sample size to detect a












where 𝑧𝑝 is the 𝑝th quantile of the standard normal distribution, DE is the design effect from




is a deflation factor which accounts for longitudinal measurements and
within-person correlation. See appendix B for more details, including a derivation.
Aswith formula (2.13), formula (3.6) can be decomposed into the standard sample size formula





depends on the exchangeable within-person correlation, 𝑇 , the total
number of measurement times, and 𝑇2, the number of measurements in the second stage of the















(𝑇 − 1)𝑇2 − 𝑇22 + 2
)
+ 4𝑇2(𝑇 − 𝑇2 − 1) + 2
)
and




𝑇2 (4𝑇2 + 2) − 𝑇
(
𝑇2(5𝑇2 + 9) + 1
)
+ 𝑇2 (𝑇2 + 2)2
)
+
𝜌(𝑇 − 1) (𝑇 − 𝑇2 − 2)
(
2𝑇𝑇2 + 𝑇 − 2𝑇2(𝑇2 + 2)
) )
A key challenge in understanding formula (3.6) is understanding the behavior of equation (3.7)
as 𝜌 and the number and timing of measurement occasions change. Note that, under working as-
sumptionA3.3, neither the numerator nor the denominator of equation (3.7) depend on the durations
of each of the stages i.e., the expression is free of 𝑡∗ and 𝑡𝑇 . The time at which re-randomization
occurs, 𝑡∗, and 𝑡𝑇 , the full duration of the study, are dictated by scientific considerations. In
particular, 𝑡∗ is determined by the length of time needed to identify individuals as responders or
non-responders to first stage treatment. When measurement occasions are equally spaced, these
scientific factors do not have an impact on the sample size requirement, nor does the choice of how
time is coded (for example, the study duration could be normalized to 1 without consequence for
sample size).
Discovery of a more interpretable upper bound on equation (3.7) has proven intractable. In-








against 𝑇 and 𝑇2 for various exchangeable within-person correlations 𝜌. We consider 𝑇 ∈
{3, . . . , 15} and 𝑇2 ∈ {1, . . . , 𝑇 − 2}. Possible values 𝑇2 are constrained so that there are al-
ways a minimum of two measurements in the first stage of the trial: one at baseline, and a second





is in fact a deflation factor and is bounded above by 1 on its domain.






































































































































































































. 𝑇 is the total number of measurement occasions, 𝑇2 of which
are in stage 2 of the SMART, with 𝑇 ∈ {3, . . . , 15} and 𝑇2 ∈ {1, . . . , 𝑇 − 2}. The function is bounded above by 1
for all 𝜌, 𝑇 , and 𝑇2, demonstrating that it is in fact a deflation factor. The function tends to decrease with 𝑇 , and is
increasingly non-monotone in 𝑇2 for higher within-person correlations 𝜌.
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Table 3.1: Example sample sizes for design II SMARTs with more than three measurement occasions. Provided sample
sizes are chosen to detect an effect size 𝛿 with 80% power with a two-sided type-I error rate of 0.05, assuming an
(exchangeable) within-person correlation 𝜌, and total number of measurement occasions 𝑇 in a design II SMART. For
each 𝑇 , we set 𝑇2 = b𝑇/2c. Response rate is 0.4 for both first-stage treatments.
Sample Size
𝛿 𝑇 𝜌 = 0 𝜌 = 0.3 𝜌 = 0.6 𝜌 = 0.8
0.3 3 559 508 358 201
5 462 427 296 164
7 382 358 245 134
9 323 307 208 113
0.5 3 201 183 129 73
5 167 154 107 59
7 138 129 89 49
9 116 111 75 41
the primary aim is a comparison of two means estimated by simple weighted averaging, so we do
not expect to benefit from repeated measurements in any way. This is easily shown analytically;
see appendix C for details. If 𝜌 = 1, the deflation factor is zero, as 𝑓 (1, 𝑇, 𝑇2) = 0 for any choice of
𝑇 and 𝑇2. Furthermore, in the three-timepoint setting, we have 𝜔(𝜌, 3, 1) = (1 − 𝜌2), the deflation
factor found in formula (2.13).
For a given 𝜌 ∈ [0, 1),𝜔 tends to decrease with𝑇 , though with diminishing returns. In settings
with high 𝜌 (say, 𝜌 ≥ 0.5) and large 𝑇 (say, 𝑇 ≥ 7), 𝜔 becomes increasingly concave in 𝑇2: for a
fixed 𝑇 , 𝜔 achieves a minimum over 𝑇2 in the interior of the domain, rather than on the boundary.
This is discussed in greater detail in section 3.3.1.
We provide example sample sizes in table 3.1 for design II SMARTs in which 𝑇2 = b𝑇/2c
and where the probability of response is equal across both first-stage treatments, 𝑟1 = 𝑟−1 = 0.4.
This choice of 𝑇2 achieves balance across the stages; if 𝑇 is odd, we slightly favor stage 1 because
we count baseline in stage 1. As expected, the sample sizes for SMARTs with three measurement
occasions correspond to those given in table 2.4. As within-person correlation and the total number
of measurement occasions increase, the sample size requirement decreases, though at a decreasing
rate. For fixed 𝜌, the benefits of adding 𝑇 diminish for higher values of 𝑇 .
This pattern, in which higher within-person correlation and more measurement occasions
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decreases sample size requirements, is a well-established phenomenon. Raudenbush and Xiao-
Feng (2001) found that the sample size requirement for detecting a between-group polynomial effect
decreases as the frequency of measurement occasions increases. Zhang and Ahn (2011b) found
similar results for the comparison of time-averaged responses in a two-arm randomized trial, noting
especially that the reduction in sample size achieved by adding measurement occasions diminishes
as 𝑇 increases. As in chapter 2, larger values of 𝜌 are generally associated with smaller sample size
requirements as well: because the correlation is within-person and the analysis is between groups,
efficiency improves with larger 𝜌 (Hedeker, Gibbons, and Waternaux 1999).
3.2.1 Simulation Study
We investigate performance of formula (3.6) using a simulation study. We hypothesize that the
formula achieve nominal power or greater (i.e., be conservative) when working assumptions A3.1
to A2.2 are satisfied.
Data were generated using the longsmart R package as described in chapter 4. We focus on
a design II SMART with either 3 or 5 measurement occasions. As in section 2.4, results from
ENGAGE informed the parameter selections for the marginal mean and variance model, but the
results are not representative of that trial. Potential response status was generated using a threshold-
based criterion such that simulated individuals with potential outcomes𝑌 (𝑑)
𝑇1





were identified as potential responders; otherwise the individual was a non-responder.




was chosen to achieve the specified response probability. All errors are
assumed to be normally-distributed.
Results of 1000 Monte Carlo simulations are given in table 3.2. In general, we achieve
80% target power or higher for 𝑇 = 3 and 𝑇 = 5 for small response rates. When one or more
response rates is 0.6 and 𝑇 = 5, empirical power tends to be significantly less than 0.8, but not
worryingly so. In these scenarios, it is non-trivial to find parameters which do not violate working
assumption A3.1(a); the results show reduced power as a result of this assumption being violated.
Further investigation is required to evaluate the performance of the sample size method under a
45
Table 3.2: Sample sizes and empirical power results for ?? SMARTs with three or more measurement occasions.
Sample sizes were chosen for an end-of-study comparison of DTRs (1, 0, 1) and (−1, 0,−1) in a design II SMART
with three or five measurement occasions. 𝛿 is the true standardized effect size as defined in equation (2.12), 𝑟 is the
common probability of response to first-stage treatment, and 𝜌 is the true exchangeable within-person correlation. 𝑛 is
computed using formula (2.13) with 𝛼 = 0.05 and 𝛾 = 0.2. Results are the proportion of 1000Monte Carlo simulations
in which we reject 𝐻0 : 𝒄>𝜽 = 0 at the 5% level.
𝑇 = 3 𝑇 = 5, 𝑇2 = 2
𝛿 𝜌 𝑟1 𝑟−1 𝑛 Power 𝑛 Power
0.3 0 0.4 0.4 559 0.804 462 0.788
0.4 0.6 524 0.813 434 0.767∗
0.6 0.4 524 0.804 434 0.760∗
0.6 0.6 489 0.825 405 0.758∗
0.3 0.4 0.4 508 0.803 427 0.804
0.4 0.6 477 0.809 400 0.770∗
0.6 0.4 477 0.790 400 0.794
0.6 0.6 445 0.810 373 0.770∗
0.6 0.4 0.4 358 0.833∗ 296 0.818
0.4 0.6 335 0.799 278 0.788
0.6 0.4 335 0.825 278 0.736∗
0.6 0.6 313 0.818 259 0.738∗
0.8 0.4 0.4 201 0.858∗ 164 0.842∗
0.4 0.6 189 0.860∗ 154 0.789
0.6 0.4 189 0.862∗ 154 0.817
0.6 0.6 176 0.815 144 †
∗ Statistically significantly different from 0.8 at the 5% level.
† Our data generative model could not accommodate this sce-
nario.
variety of scenarios, including when assumptions are violated in a principled way.
3.3 Cost Considerations for Longitudinal SMARTs
Managing trial costs are a key reality of designing experiments, and this is no different for SMARTs.
Here, we develop tools which can aid clinicians and applied statisticians in choosing both sample
size and the number ofmeasurement occasions to achieveminimum total cost, subject to a constraint
on statistical power.
There are a variety of costs involved in conducting any study, including personnel and staffing
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costs, costs of administering the interventions, data management costs, etc. For our purposes, we
consider only costs related to recruiting individuals into the trial and measuring their outcomes.
Note that we consider only costs directly related to participants: overhead and other costs (e.g.,
data management, salaries, etc.) are taken as sunk.
We examine this problemgiven a specific scientific context; that is, we consider the intervention
options in the SMART, as well as the desired type-I error rate, target power, and target standardized
effect size, to be fixed a priori. This also fixes 𝜌 and the response rates 𝑟1 and 𝑟−1, as these are
characteristics of the interventions in the trial and not design choices.
3.3.1 Minimizing Recruitment Costs
Suppose an investigator is interested primarily in minimizing the cost of recruiting individuals into
a longitudinal SMART, or, equivalently, minimizing the sample size requirement. This may be of
particular interest when the target population is hard to reach, for example. As seen in figure 3.2,
the sample size computed by formula (3.6) decreases with the number of measurement occasions
𝑇 ; the most naive strategy for minimizing sample size is to measure the outcome as many times as
is feasible. This is not a very practical recommendation, however: a large number of measurement
occasions may be quite burdensome to participants, potentially leading to dropout. We therefore
proceed assuming that the investigator has chosen 𝑇 a priori.
The multi-stage nature of SMARTs introduces a question of how best to allocate measurement
occasions across stages. For instance, formula (3.6) is for an end-of-study comparison; because of
this, we expect that adding measurement occasions in the second stage of the trial will yield greater
reductions in sample size requirements than will adding measurements in the first stage. Here, we
investigate the allocation of measurement occasions in the first and second stages of a SMART
which produces the smallest sample size requirement (and therefore the smallest total recruitment
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subject to 𝑇2 ∈ {1, . . . , 𝑇 − 2} .
(3.8)
As above, we require at least two measurements in stage 1. Minimizing the sample size












subject to 𝑇2 ∈ {1, . . . , 𝑇 − 2} .
(3.9)
We call the solution to optimization problem (3.9) 𝑇n2 . Since equation (3.7) is free of stage duration
under working assumption A3.3, we set 𝑡1 = 0, 𝑡∗ = 1, and 𝑡𝑇 = 2 without loss of generality.
Optimization problem (3.9) is difficult to solve analytically. However, the feasible set of 𝑇2 is
relatively small, so solutions can be quickly and easily obtained using grid search. For a given 𝜌,




, and find 𝑇n2





in section 3.2 provides evidence for our earlier conjecture about
𝑇n2 : as 𝑇2 increases toward 𝑇 − 2 (i.e., as more of the total measurement occasions in the trial are
placed in the second stage) 𝜔 tends to decrease. However, careful inspection of figure 3.2 reveals




achieves a minimum at 𝑇2 < 𝑇 − 2. This
suggests that it is sub-optimal to measure the outcome as many times as possible in the second
stage: some balance across stages is favored.
In figure 3.3, we plot 𝑇n2 against 𝑇 for various choices of 𝜌. In each plot, we include the lines
𝑇n2 = 𝑇 − 2 (upward-facing triangles) and 𝑇
n
2 = b𝑇/2c (downward-facing triangles). Recall that 𝑇
is fixed a priori. The former line represents the design strategy of including as many measurement
occasions in stage 2 as possible; the latter corresponds to balancing measurements across stages.
For smaller 𝜌 and/or smaller 𝑇 , 𝑇n2 = 𝑇 − 2: the optimal allocation strategy is to maximize the
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Figure 3.3: Optimal allocation of equally-spaced measurement occasions in stage 2 to minimize sample size for various
within-person correlations 𝜌. The trajectory with filled circles represents 𝑇n2 , the optimal allocation, for a given 𝑇 . The
trajectory with upward-facing triangles is the line 𝑇2 = 𝑇 − 2, the maximum number of measurements allowed in stage
2. The trajectory with downward-facing triangles is 𝑇2 = b𝑇/2c, representing balanced allocation of measurements
across stages. For 𝑇 > 4, it is optimal to allocate more measurements to stage 1 than to stage 2.
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number of measurement occasions in the second stage of the trial. For 𝜌 = 0, it is easy to show
that the partial derivatives of 𝜔 in 𝑇 and 𝑇2 are strictly negative for 𝑇 ≥ 3 and 𝑇 ≤ 𝑇 − 2, implying
that it is always better to add measurements in stage 2. This remains true for small, nonzero values
of 𝜌.
Recall that model (3.1) is unsaturated for 𝑇 > 3 and 𝑇2 > 1. For an end-of-study comparison,
we believe that gains in power relative to the three-measurement setting are achieved primarily
through smoothing the mean model in the second stage. The sample size requirement is directly
proportional to the variance of the contrast (see appendix B). When 𝜌 = 0, any efficiency gain
in estimating the contrast (meaning, any reduction in the sample size requirement) cannot be
attributed to repeated measurements on the same individual; instead, the reduction must be derived
from improved model fit. As the number of measurement occasions in stage 2 increases, we are
able to estimate the mean end-of-study difference with greater precision. We believe this is driven
primarily by increased effective sample size: each additional measurement occasion provides more
data with which to estimate regression parameters.
For higher values of 𝜌, it becomes sub-optimal to maximize the number of measurements
in stage 2 as the total number of measurements 𝑇 increases. This is reflected in the concavity
seen in figure 3.2, as well as the deviation of the filled circles from the 𝑇 = 𝑇 − 2 trajectory in
figure 3.3. For larger 𝜌, each additionalmeasurement of an individual yieldsmore information about
that individual’s outcome trajectory, which in turn lowers the variance of the model parameters.
Therefore, we expect diminishing returns of adding (exchangeable) measurements in the second
stage of the SMART for moderate to large 𝜌. Because the contrast (3.5) involves first-stage
quantities, it becomes advantageous to also smooth the model in the first stage of the SMART for
large 𝜌 and large 𝑇 .
3.3.2 Minimizing Per-Patient Costs
Often, concerns about large sample sizes for trials are related to overall study costs: recruitment of
participants can be expensive, and so larger sample sizes correspond to more expensive trials. As
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we have seen, the repeated measures in a longitudinal SMART allow for gains in efficiency which
can reduce the sample size requirement. If an investigator’s interest is in reducing overall study
expenditures, we may be able to trade off between sample size and the number of measurement
occasions in order to achieve a minimum cost.
Suppose the cost of recruiting one individual into the study is 𝐶𝑅, and let 𝐶1 and 𝐶2 be the
costs of measuring their outcomes in the first and second stages of the SMART, respectively. For
a SMART with 𝑛 participants and 𝑇 total measurement occasions, 𝑇2 of which are in stage 2, the
total per-participant cost of the trial is
𝐶 (𝑛, 𝑇, 𝑇2) = 𝑛
(
𝐶𝑅 + (𝑇 − 𝑇2)𝐶1 + 𝑇2𝐶2
)
. (3.10)
𝐶𝑅, 𝐶1, and 𝐶2 can include a variety of participant-specific costs, including those related to adver-
tising for recruitment and incentives for measuring the research outcome. While equation (3.10)
does not directly accommodate variable incentives within each stage, investigators could average
these costs across measurement occasions.
Our goal is to solve the optimization problem
minimize
𝑛,𝑇,𝑇2
𝐶 (𝑛, 𝑇, 𝑇2)
subject to 1 − 𝛾 ≥ 0.8
subject to 𝑇 ∈
{
3, 4, . . . , 𝑇max
}
,
𝑇2 ∈ {1, 2, . . . , 𝑇 − 2}
(3.11)
where 1−𝛾 is the power of the end-of-study comparison of embedded DTRs for which the SMART
is sized. The power constraint is satisfied by choosing 𝑛 according to formula (3.6). Therefore, we
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This is a nonlinear integer program for which it is difficult to find a general solution. As in sec-
tion 3.3.1, we investigate numerically across a variety of scenarios. We also make the simplification
of equally-spaced measurement occasions in both stages, as per working assumption A3.3.
Notice first that the objective function in optimization problem (3.12) involves a number
of terms which are constant in 𝑇 and 𝑇2. The cost-optimal number of measurement occasions,
therefore, does not depend on features of the hypothesis test (significance level, target power), the
target effect size, response rate, or even the design of the SMART (through the design effect DE).
Certainly the total costs required will change based on these quantities since they change the sample
size requirement; however, in order to understand the behavior of the objective function with regard
to the solutions of optimization problem (3.12), we need only consider 𝜌, 𝑇 , and 𝑇2. Because the
objective function uses the form of 𝑛 from formula (3.6), the power constraint is guaranteed to be
satisfied under working assumptions A3.1 to A3.3.
The feasible set for optimization problem (3.12) is theoretically unbounded; practically, it
is not. Most SMARTs with longitudinal outcomes, to our knowledge, employ a relatively small
number of measurement occasions. Three measurement occasions are common (Naar-King et
al. 2016), as are five (McKay et al. 2015; Kilbourne et al. 2018). To our knowledge, SMARTs with
more than 15 measurement occasions are rare, and often driven by questions about the effects of
interventions on relatively fine time scales. Typically, end-of-study comparisons do not motivate
this type of (intensive longitudinal) data collection, so we restrict our focus to SMARTs in which
the outcome is measured 15 times or fewer (Walls and Schafer 2006).
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In table 3.3, we compile the total number of measurement occasions 𝑇cost and the number
of occasions in stage 2, 𝑇cost2 , which solve optimization problem (3.12) for a variety of costs and
within-person correlations 𝜌. We consider 𝑇 ∈ {3, . . . , 15}. Because the objective function is
linear in𝐶𝑅, 𝐶1, and𝐶2, their exact values only affect the value of the minimum cost, not the values
of the minimizers. We therefore focus on the costs of recruiting one individual relative to that of
measuring an individual once by considering the ratios 𝐶𝑅/𝐶1 and 𝐶𝑅/𝐶2.
When it is relatively cheap to recruit, meaning that 𝐶𝑅 is similar to 𝐶1 and 𝐶2, the objective
function strongly favors recruiting more individuals in favor of adding measurement occasions.
When 𝐶𝑅, 𝐶1, and 𝐶2 are similar, 𝑇cost is often 3: the most cost-effective way to achieve the
target power in a longitudinal SMART is to measure the outcome infrequently in a larger number
of participants. When 𝜌 = 0, 𝑇cost and 𝑇cost2 are the maxima of their domains when recruitment
becomes even slightly more expensive than second-stage measurements. For even small non-zero
values of 𝜌, the preference for 𝑇cost = 3 is maintained generally, except when 𝐶𝑅 is two to four
times 𝐶2 and similar to 𝐶1. The majority of remaining settings examined favor maximizing the
total number of measurement occasions.
The solutions in table 3.3 suggest that there is little middle ground in the trade-off between
sample size and number of measurement occasions when optimizing for cost. In most situations,
the solution to optimization problem (3.12) is either 𝑇cost = 3, the minimum, or 𝑇cost = 15, the
maximum number of measurements we are willing to consider. For small-to-moderate non-zero
within-person correlations 𝜌 in which𝐶𝑅 is not too much larger than𝐶1 or𝐶2, the trade-off is more
balanced between 𝑛 and 𝑇 : 𝑇cost is neither the maximum nor minimum of its domain.
Curiously, the allocation of measurement occasions across stages, i.e., 𝑇cost2 exhibits more
variability than does 𝑇cost. Note that, in general, 𝑇cost2 ≠ 𝑇
n
2 ; i.e., the solutions to optimization
problems (3.9) and (3.12) do not always coincide. Recall that 𝑇n2 minimizes the sample size
requirement given equal spacing as in working assumption A3.3 and fixed 𝜌 and 𝑇 . The fact that
𝑇cost ≠ 𝑇n for 𝜌 ≠ 0 makes the 𝑛-versus-𝑇 trade-off more apparent: it is not always cost-optimal to
minimize sample size, even when recruitment is much more expensive than measurement. This is
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Table 3.3: Total number of measurement occasions 𝑇cost and number of second-stage measurements 𝑇cost2 (in parenthe-
ses) which minimize trial cost for a design II SMART. Solutions are obtained by solvingoptimization problem (3.12)
for 𝑇 ∈ {3, . . . , 15} and 𝑇2 ∈ {1, . . . , 𝑇 − 2}. 𝐶𝑅 is the cost of recruiting one participant into the SMART, 𝐶1 the cost
of measuring one participant once in stage 1, and 𝐶2 the cost of measuring one participant once in stage 2. As 𝐶𝑅
becomes large relative to 𝐶1 and, particularly, 𝐶2, costs are minimized by measuring the outcome as many times as is
feasible.
𝑇cost (𝑇cost2 )
𝐶𝑅 𝐶1 𝐶2 𝜌 = 0 𝜌 = 0.3 𝜌 = 0.5 𝜌 = 0.7
1 1 1 3 (1) 3 (1) 3 (1) 3 (1)
1 0.75 15 (13) 3 (1) 3 (1) 3 (1)
1 0.5 15 (13) 5 (3) 3 (1) 3 (1)
0.75 1 3 (1) 3 (1) 3 (1) 3 (1)
0.5 1 3 (1) 3 (1) 3 (1) 3 (1)
2 1 1 15 (13) 3 (1) 3 (1) 3 (1)
1 0.75 15 (13) 3 (1) 3 (1) 3 (1)
1 0.5 15 (13) 7 (5) 6 (4) 3 (1)
0.75 1 15 (13) 3 (1) 3 (1) 3 (1)
0.5 1 3 (1) 3 (1) 3 (1) 3 (1)
5 1 1 15 (13) 7 (5) 5 (3) 15 (7)
1 0.75 15 (13) 8 (6) 15 (9) 15 (8)
1 0.5 15 (13) 12 (10) 15 (10) 15 (9)
0.75 1 15 (13) 6 (4) 15 (8) 15 (7)
0.5 1 15 (13) 15 (8) 15 (7) 15 (6)
10 1 1 15 (13) 15 (10) 15 (8) 15 (7)
1 0.75 15 (13) 15 (11) 15 (9) 15 (8)
1 0.5 15 (13) 15 (12) 15 (10) 15 (9)
0.75 1 15 (13) 15 (9) 15 (8) 15 (7)
0.5 1 15 (13) 15 (8) 15 (7) 15 (7)
100 1 1 15 (13) 15 (10) 15 (8) 15 (7)
1 0.75 15 (13) 15 (10) 15 (8) 15 (8)
1 0.5 15 (13) 15 (10) 15 (8) 15 (8)
0.75 1 15 (13) 15 (10) 15 (8) 15 (7)
0.5 1 15 (13) 15 (10) 15 (8) 15 (7)
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evident in figure 3.4: as 𝐶𝑅 grows relative to 𝐶1 and 𝐶2, or for higher within-person correlation,
the objective function becomes increasingly concave.
Recall that our intuition around the results in section 3.3.1 and figure 3.3 is that the benefit of
allocating more measurements in the second stage is primarily related to smoothing: the efficiency
gained by better estimating the second-stage trajectory is important for reducing the sample size
requirement for small 𝜌. For larger 𝜌, we favor more balanced allocation of measurements across
stages, presumably due to the within-person correlation providing more information about the
trajectories in each stage. In table 3.3, the benefits of the within-person correlation become
apparent at lower 𝜌 as well: the cost optimization favors balance across stages.
3.4 Practical Implications for Designing Longitudinal SMARTs
Conversations between statisticians and investigators about sample size can be challenging, for a
variety of reasons. Boen and Zahn (1982), in describing their experiences as statistical consultants,
remark that investigators typically have firm upper (and sometimes lower) bounds on sample size
which are often dictated by personal experience, disciplinary traditions, or budget constraints.
Financial considerations are often of particular importance At the same time, that a study is sized
to detect a relevant effect with at least 80% power is often an implicit or explicit requirement for
many funding agencies.
The methods presented in section 3.3 allow for a reframing of conversations about sample
size for longitudinal SMARTs by introducing the ability to balance sample size and the number of
measurement occasions to achieve specified power while minimizing cost. This requires elicitation
of more parameters on the part of the statistician, which is often nontrivial but opens the door to
more collaborative discussions of trial design (Lenth 2001).
Consider an investigator who wishes to design a longitudinal SMART powered for the primary
aim of comparing two embedded DTRs which recommend different first-stage treatments. As a






















































𝐶𝑅 = 1 𝐶𝑅 = 10 𝐶𝑅 = 100




· 𝐶 (𝑛, 𝑇, 𝑇2) for minimizing per-participant trial costs. Each plot is
of the (scaled) objective function in optimization problem (3.12) for various choices of within-person correlation 𝜌 and
recruitment cost 𝐶𝑅. For all scenarios, stage-1 and stage-2 measurement costs are set to 1: 𝐶1 = 𝐶2 = 1. For larger 𝜌,
the objective function becomes increasingly concave over the optimization domain (much more so than in figure 3.2).
𝑇cost2 tends to be smaller than 𝑇
n
2 from figure 3.3.
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over time for each of the DTRs, perhaps to investigate delayed effects of treatments (Nahum-Shani
et al. 2020). Their initial plan is to measure the outcome four times: once at baseline, once at the
end of the first stage, and twice in the second stage.
Formula (3.6) was designed to involve only quantities which are relatively easy to find from
existing literature or domain knowledge, so the statistician’s work with this investigator may begin
fairly typically. The statistician will need to elicit a target effect size, estimated probability of
response to first-stage treatments, and within-person correlation. Formula (3.6) enables easy
computation of sample size given these quantities. However, the result may be practically infeasible
due to budget constraints or other realities of running a trial.
The trade-offs discussed in section 3.3 allow the statistician to work collaboratively with the
investigator to modify the number and timing of measurement occasions to minimize trial costs.
By eliciting additional information such as the maximum number of times the investigator would
be willing to measure the outcome, approximate costs of those measurements, and the cost of
recruitment, the statistician can shift the conversation from one about sample size to one about trial
design more broadly.
Table 3.3 and figure 3.4 suggest that, for most realistic scenarios in which recruitment is much
more expensive than measurement, overall costs are lower in trials with more measurement occa-
sions. By working with the investigator to identify the largest number of measurement occasions
they would consider, the statistician can address the investigator’s feasibility concerns with regard
to sample size and total cost of the trial, while still maintaining target power. This will allow the
statistician and investigator to collaboratively maximize what can be done with the trial’s finite
resources.
This is explicitly a different framing of the cost problem than that considered by, for example,
Bloch (1986), Liu and Colditz (2017), and Zhang and Ahn (2011a). These authors all examine
financial considerations in randomized trials, but with an eye towards maximizing statistical power
given a fixed budget. This approach has the advantage of recognizing and working within monetary
constraints provided by the investigator, but may under-power the trial. Our approach acknowledges
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the reality that achieving 80% power is an important convention in trial design and imposes that as
the primary constraint. We do not guarantee that the solutions to optimization problem (3.12) will
yield a total cost that is lower than a given budget.
The cost function equation (3.10) is easily extensible. 𝐶1 and 𝐶2 might, for instance, incorpo-
rate some notion of burden on behalf of the participant or clinical staff. The function could also be
designed to incorporate non-constant costs of measurement within stages, which might be the case
if incentives for participants change over time. Furthermore, while an investigator may be willing
to measure the outcome 𝑇max times, they may have a strong preference against including more than
𝑇pref < 𝑇max occasions. This preference can be incorporated by imposing a penalty on 𝑇 > 𝑇pref in




Software for Designing Longitudinal SMARTs
As interest in SMARTs grows, and as the design is extended to accommodate more complex
scientific settings, there is a clear need for the development of software that would allow domain
scientists and applied statisticians to perform simulation-based sample size and power calculations.
An important challenge here is to make the software general enough to be used across a number of
different types of SMART designs (e.g., three stages of randomization), yet not so flexible that it is
difficult to use. The benefit of this is the ability to examine the power for various different scientific
questions given a single data generative model and for many other types of SMARTs.
In this chapter, we develop a framework for simulating data from a SMART with a continuous
longitudinal outcome and introduce the R package longsmart, which implements the data generative
model as well as the analytic methods described in chapter 3. We discuss the specifics of the
generative model in section 4.1, then illustrate how longsmart can be used to design and simulate
longitudinal SMARTs in section 4.2
4.1 A Data-Generative Procedure for Longitudinal SMARTs
The analytic methods for SMARTs described in chapters 2 and 3 allow for inference marginal
over the tailoring variable. Models (2.1) to (2.3) can be used to estimate mean potential outcomes
E[𝑌 (𝑎1,𝑎2R,𝑎2NR)] for a DTR (𝑎1, 𝑎2R, 𝑎2NR) averaging over response status. However, data are
observed conditionally on response: a single participant can only be a responder or a non-responder.
This is a key challenge in developing data-generative models for SMARTs.
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When a continuous outcome is observed once at the end of a SMART, this challenge is easily
overcome using the laws of total probability and variance; similarly for other types of outcomes
(Ogbagaber, Karp, and Wahed 2016; Kidwell et al. 2018). Generating longitudinal data presents
a more complex challenge: the outcome is observed across stages, the tailoring variable is likely
related to previously-observed outcome measurements, and it may be necessary to precisely control
the marginal covariance structure of the outcomes. The challenge related to the tailoring variable,
in particular, is non-trivial.
The primary goal of the data generative procedure described here is to enable simulation
of longitudinal SMARTs with known marginal means and covariances for each embedded DTR.
Because the sample size methods described in chapters 2 and 3 assume a particular marginal
covariance structure, it is important for testing these methods that the data generative model satisfies
this assumption. The procedure requires a mean model 𝝁(𝑑) (𝜷) for each embedded DTR 𝑑, a target
marginal variance structure 𝚺(𝑑) for each embedded DTR, as well as second-stage means and
covariance “components” (see below) for responders to each first-stage treatment. The procedure
also requires methods for identifying responders and non-responders, and for computing means and
covariances of stage-1 outcomes conditional on response. We write a(𝑑)
𝑗




1 ) = 𝑟]
and 𝚵(𝑑) (𝑟) = Var
(
𝒀 (𝑑) | 𝑅(𝑎
(𝑑)
1 ) = 𝑟
)
, with ( 𝑗 , 𝑘)th element b (𝑑)
𝑗 𝑘
.
In order to develop a realistic data generative model, we attempt to follow as closely as possible
the way in which data is accumulated in a SMART. Let 𝒀 𝑖, 𝑗 :𝑘 be the vector of the 𝑖th individual’s
outcomes at measurement occasions 𝑗 , 𝑗 + 1, . . . , 𝑘 , for 𝑘 > 𝑗 . Recall from section 2.2.1 that the
data collected from the 𝑖th participant in the SMART is of the form
(
𝑿𝑖, 𝑌𝑖,1, 𝐴𝑖,1,𝒀 𝑖,2:𝑇1 , 𝑅𝑖, 𝐴𝑖,2,𝒀 𝑖,𝑇1+1:𝑇
)
,
where 𝑇1 = 𝑇 −𝑇2 is the number of measurement occasions in stage 1. For simplicity, we currently
ignore baseline covariates 𝑿; future work will extend the generative model described below to
accommodate baseline covariates.
60
4.1.1 Simulation of Potential Outcomes
To guarantee that consistency (identifiability assumption I2; see appendix A) is satisfied, we





𝑡 ] for some DTR 𝑑 ∈ D (D as defined in section 2.2.2). Suppose we wish to
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, 𝑗 = 1, . . . , 𝑇1, (4.1)
where 𝑏 (𝑑)
𝑗 𝑘
are constants chosen to achieve the desired marginal covariance structure and 𝜖 𝑗 ,𝑖 is






















Note that for the baseline measurement ( 𝑗 = 1), we set the sum from 𝑘 = 1 to 0 to zero.
Equation (4.1) induces within-person correlation by explicitly making each potential outcome











desired correlation structure; we discuss this in more detail below. Note that the choice of 𝒄(𝑑)
𝑗
does
not affect the mean of 𝑌 (𝑑)
𝑖, 𝑗
, as the summand in equation (4.1) is mean-zero.





), where 𝑔𝑎1 : R𝑇1 → {0, 1} is any
function of stage-1 outcomes that returns 1 if the individual is a responder and 0 otherwise. As an













Here, an individual is a (potential) responder to first-stage treatment 𝑎1 if their (potential) outcome
at time 𝑡𝑇1 = 𝑡∗ exceeds some threshold ^𝑎1 and a non-responder otherwise. We discuss this in more
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detail in section 4.1.3.
In the second stage, we generate data condtitionally on response status, such that, for 𝑗 =































































𝚵(𝑑) (𝑟)1: 𝑗−1,1: 𝑗−1𝒃 (𝑑)𝑗 . (4.5)
Note that, given the marginal mean model 𝝁(𝑑) , we need only specify either 𝝂(𝑑) (1) or 𝝂(𝑑) (0) for













1 ) = 1
))
𝝂(𝑑) (0). (4.6)
It remains to show how to choose 𝒃 (𝑑)
𝑗
to achieve the desired marginal covariance structure.




= 𝚺(𝑑)1: 𝑗−1, 𝑗 . (4.7)
As an example, if 𝚺(𝑑) = (𝜎 (𝑑))2Exch𝑇 (𝜌(𝑑)), i.e., the true correlation structure is exchangeable








1 + ( 𝑗 − 1)𝜌(𝑑)
)
for all 𝑘 = 1, . . . , 𝑗 − 1.
In the second stage of the SMART, data is generated conditionally on response status, so
equation (4.7) becomes, for 𝑗 = 𝑇1 + 1, . . . , 𝑇 ,
𝚵(𝑑) (𝑟)1: 𝑗−1,1: 𝑗−1𝒃 (𝑑)𝑗 = 𝚵
(𝑑) (𝑟)1: 𝑗−1, 𝑗 (4.8)
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for all 𝑑 ∈ D and 𝑟 ∈ {0, 1}. As we discuss below, there is not a closed-form expression for𝚵(𝑟)−1,
so we cannot give an expression for 𝑐(𝑑)
𝑗 ,𝑘
; however, equation (4.8) is easy to solve computationally.
We now describe how the generative model elicits and computes variances for second-stage










where 𝚵(𝑑)11 (𝑟) ∈ R
𝑇1×𝑇1 and 𝚵(𝑑)22 (𝑟) ∈ R
𝑇2×𝑇2 . Note that 𝚵(𝑑)11 (𝑟) = Var(𝒀
(𝑑)
1: 𝑗−1 | 𝑅
(𝑑) = 𝑟) is
determined by the choice of response status and is therefore fixed. In general, 𝚵(𝑑) (𝑟) does not
respect the marginal covariance structure, and is typically unstructured.
Both 𝚵(𝑑)12 (𝑟) and 𝚵
(𝑑)
22 (𝑟) need to be specified for either 𝑟 = 1 or 𝑟 = 0. This involves
identifying stage-2 and “cross-stage” covariances, both conditional on response. By design, the
re-randomizations in SMARTs produce subsets of participants consistent with more than one DTR;
recall that, for example, responders in design II are consistent with both embedded DTRs which
recommend the same first-stage treatment. This means that we need only specify 𝚵(𝑑)12 (𝑟) and
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) (
𝝂(𝒅) (1) − 𝝂(𝑑) (0)
)⊗2
. (4.10)
In sum, the process of generating potential outcomes in a longitudinal SMART involves the
following steps:
1. For each embedded DTR 𝑑, specify 𝝁(𝑑) , the marginal mean outcome at all measurement
occasions and 𝚺(𝑑) , the marginal variance of the outcome.
2. Specify a response function 𝑔𝑎1 (𝒀
(𝑑)
1:𝑇1
) which assigns (potential) response status based on
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potential outcomes in the first stage of the SMART.
3. For one DTR that recommends each first-stage treatment and one response status 𝑟, specify
𝚵(𝑑)12 (𝑟) and 𝚵
(𝑑)
22 (𝑟).
4. For the 𝑗 thmeasurement occasion in stage 1, 𝑗 = 1, . . . , 𝑇1, find 𝒄(𝑑)𝑗 by solving equation (4.7).
Simulate mean-zero noise 𝜖 (𝑑)
𝑗
with variance (4.2) (using, e.g., a normal distribution), then
generate potential outcomes 𝑌 (𝑑)
𝑖, 𝑗
using equation (4.1).







for each simulated individual.
6. For each treatment path, find 𝝂(𝑑) (𝑟) and 𝚵(𝑑) (𝑟) using equations (4.6) and (4.10). For








) with variance as in equation (4.5) and generate second-stage potential outcomes
using equation (4.4).
In table 4.1, we show that the target marginal variance structures are achieved using this data
generative model for three measurement occasions with an exchangeable marginal correlation
structure.
4.1.2 “Observing” Potential Outcomes
Once the potential outcomes data is generated following the procedure in section 4.1.1, we will
“observe” a subset of those outcomes for each participant in the SMART according to simulated
treatment assignment. Recall that the potential baseline measure, 𝑌 (𝑑)
𝑖,1 , is the same for all DTRs 𝑑,
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Table 4.1: Target and estimated marginal variance matrices from the data generative model described in section 4.1.1.
The “unstructured estimate” is produced by estimating the variance at each timepoint and for each DTR, and correlation
for each DTR using the unstructured estimate in table 2.2, then averaging over DTRs. The “exchangeable estimate”
is computed by assuming variance is constant over time and DTR, and using the exchangeable estimate of 𝜌 from
table 2.2, averaged over DTRs. The exchangeable estimate is used in simulations assuming working assumption A2.2
is satisifed.





















































𝐴𝑖,1 | 𝑌𝑖,1 ∼ 2 ∗ Bernoulli(𝜋1) − 1












𝐴𝑖,2 | 𝑅𝑖, 𝐴𝑖,1,𝒀 𝑖,1:𝑇1 ∼ 2 ∗ Bernoulli(𝜋2) − 1




where 𝑍𝑘 is a function which maps observed treatment history and (if applicable) response status
to the potential outcome 𝒀 (𝑑)𝒕,𝑖 consistent with that history. The form of 𝑍𝑘 is given in table A.1, and
varies by SMART design.
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4.1.3 Threshold-Based Response Status
A challenging aspect of generating data for longitudinal SMARTs is the fact that analyses are
(typically) conducted marginally over response status. When generating data, however, it necessary
to understand means and variances of stage-1 outcomes conditional on response status. This is non-
trivial, as it is, in some sense, conditioning on “the future”: response status is often a function of
stage-1 outcomes. Our need for this is driven primarily by a need to ensure that the correct marginal
variance structure is achieved, and because working assumption A3.1 depends on these quantities.
Here, we discuss how these conditional means and variances are computed for a “threshold-based”
response status, as defined in equation (4.3). Here, we assume errors 𝜖 (𝑑)
𝑗
are jointly normally
distributed in the first stage.
At 𝑡∗ = 𝑡𝑇1 , the measurement time to which the threshold is applied, the potential outcomes























where 𝜙 is the standard normal density and Φ is the standard normal cumulative distribution
function.
















































By properties of the bivariate normal distribution,
`
(𝑑)
































































For 𝑗 = 1, . . . , 𝑇2, we can find themean and variance of the potential outcoems under each first-stage
treatment conditional on response using equation (4.12).






given response status, which is necessary to compute conditional covariances.
The details of this computation are not particularly illuminating; we refer the interested reader to
the documentation for the companion R package longsmart. Similar derivations are required for
other definitions of response to ensure that working assumption A3.1 is satsified.
4.2 The longsmart R Package
The longsmart package for R (available at https://github.com/nseewald1/longsmart) implements the
generative model described in section 4.1 as well as the methods for sample size described in
chapter 3. The package enables relatively easy, customizable simulation of data arising from
longitudinal SMARTs and provides users with tools to design such trials by choosing sample size
and the number and timing of measurement occasions, keeping trial budget in mind.
A key idea that runs throughout the package is the identification of a SMART design via
randomization probabilities. We assert that a SMART design can be uniquely identified by a set of
randomization probabilities 𝜋. In a two-stage SMART with at most two treatment options at each
randomization, 𝜋 = {𝜋1, 𝝅2R, 𝝅2NR}, where 𝜋1 = 𝑃(𝐴1 = 1),
𝝅2R =
(







𝑃(𝐴2NR = 1 | 𝐴1 = 1, 𝑅 = 0), 𝑃(𝐴2NR = 1 | 𝐴1 = −1, 𝑅 = 0)
)>
.
We will say that 𝑃(𝐴2NR = 1 | 𝐴1 = 1, 𝑅 = 0) = 0 if responders to first-stage treatment 𝐴1 = 1 are
not re-randomized; similarly with other elements of 𝝅2R and 𝝅2NR. For example, we could identify
a design II SMART with equal randomizations wiht 𝜋 =
{
0.5, (0, 0)>, (0.5, 0.5)>
}
.
We first discuss longsmart’s implementation of the design methods from chapter 3, then how it
can be used to simulate data.
4.2.1 Tools for Designing SMARTs
An important function available in longsmart is the smart_size() function, which implements the
general sample size formula for longitudinal SMARTs in formula (3.6). The package implements a
version of the within-person deflation factor 𝜔 which allows for measurement occasions which are
not equally spaced, given as equation (B.26) in appendix B.3.
The smart_size() function takes a variety of inputs which describe the SMART for which
sample size is desired. Users specify the design of the SMART using the randomization argument,
which encodes 𝜋 as discussed above. The function uses this to compute the appropriate design effect
DE in formula (3.6). Other design-related inputs include mTimes, the vector of measurement times,
and tStar, the time measurement time immediately after which participants are re-randomized.
smart_size() also elicits information about the interventions under study through rho, the within-
person correlation, and pR, a vector of probabilities of response.
Results from smart_size() are of class power.htest, so the output is presented to the user
in a familiar way, similar to built-in power functions such as power.t.test(). An example is in
program 4.1. As with other power functions in base R, the user can alternatively specify power =
NULL or sig.level = NULL to have the function compute power or significance level given a sample
size n. The default randomization argument yields a prototypical SMARTwith equal randomization
throughout.
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Program 4.1: Use of the smart_size() function to compute sample size for a longitudinal SMART. The target
standardized effect size is 𝛿 = 0.3, the outcome ismeasured at times 0-4, and re-randomization occurs aftermeasurement
time 2. We assume 𝜌 = 0.3, and 40% response rates to both first-stage treatments. The minimum-required sample size
to compare two embedded DTRs with different first-stage treatments is 427.
library(longsmart)
smart_size(n = NULL, delta = 0.3, mTimes = c(0, 1, 2, 3, 4),
tStar = 2, power = 0.8, pR = c(0.4, 0.4), rho = .3)
# Longitudinal SMART power calculation
#
# n = 427
# delta = 0.3
# sig.level = 0.05
# power = 0.8
# alternative = two.sided
# meas.times = 0, 1, 2, 3, 4
# t.star = 2
# rho = 0
# pR = 0.4, 0.4
#
# NOTE: Power for a SMART in which the probability of
# randomization to first-stage treatment A1 = 1 is 0.5;
# responders are not re-randomized; non-responders are
# re-randomized to second-stage treatment A2 = 1 with
# probability 0.5.
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Program 4.2: Use of the optimize_cost() function to find the number and allocation of measurement occasions
which minimize per-participant trial costs. The investigator wishes to detect an effect size 𝛿 = 0.4 and is planning a
16-week study in which each stage is 8 weeks long. They will consider at most 8 measurement occasions.
optimize_cost(delta = 0.4, tStar = 8, tMax = 16, numTimesMax = 8,
rho = 0.36, pR = c(0.4, 0.5), cost_recruit = 300,
cost_meas = 20)
# Cost-optimal measurement allocation for longitudinal SMART
#
# Call:
# optimize_cost(delta = 0.4, tStar = 8, tMax = 16, numTimesMax = 8,
# rho = 0.36, pR = c(0.4, 0.5), cost_recruit = 300,
# cost_meas = 20)
#
# Optimal total number of measurements: 8
# Optimal number of measurements in stage 2: 5
# Sample size required: 160
# Total cost: 73,600
A second useful design tool in longsmart is the optimize_cost() function, which implements
grid search to solve optimization problem (3.12). Given the same SMARTdesign-related arguments
as sample_size() (i.e., delta, rho, pR, and randomization), the maximum number of measurement
occasions the user is willing to consider in in the SMART (numTimesMax), and costs of recruitment
(cost_recruit) and measurement (cost_meas), optimize_cost() will identify the combination of 𝑇
and 𝑇2 which minimize total cost of the trial.
Consider an example in which an investigator will run a 16-week design II SMART with
re-randomization after week 8. They are willing to consider at most 8 measurement occasions.
The hypothesized response rate to first-stage treatments 𝐴1 = 1 and 𝐴1 = −1 are 0.4 and 0.5,
respectively, and previous literature suggests an exchangeable within-person correlation of 0.36.
The cost of recruiting one participant is expected to be $300; the cost of eachmeasurement is $20 for
both stages. The study should be sized to detect an effect size of 0.4 with at least 80% power using
a two-sided level-0.05 test. The solution to optimization problem (3.12), shown in program 4.2, is
to use 𝑇cost = 8 total measurements, placing 𝑇cost2 = 5 in the second stage. The investigator should
measure the outcomes at 𝒕 = {0, 4, 8, 9.6, 11.2, 12.8, 14.4, 16} weeks. The required sample size is
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160 participants. This is the cheapest of all possible configurations of 𝑇cost and 𝑇cost2 that achieves
80% power; the total cost of recruitment and measurement is $73,600.
Note that if the investigator is interested solely in minimizing the sample size requirement, as
in section 3.3.1, they can simply set cost_meas to 0 in optimize_cost().
4.2.2 Tools for Simulating Longitudinal SMARTs
The longsmart package is designed with a particular eye towards simplifying the process of simu-
lating data from longitudinal SMARTs. Working with the generative model in section 4.1 can be
challenging; longsmart attempts to meet that challenge by creating user-friendly interfaces.
The primary function used for simulating data from a longitudinal SMART is design_smart().
This function creates an object of class longsmartDesign, and is the foundation of all simulation-
related functions in longsmart. A longsmartDesign object is a list which completely describes the
SMART the user wishes to simulate. These properties include the randomization set 𝜋, the times
at which the outcome is measured, and marginal and conditional means and variances for all
embedded DTRs and treatment paths at all measurement occasions. By default, design_smart() is
to use the threshold-based response status described in section 4.1.3, but the user can specify any
function with appropriate inputs and returned objects (see below).
Consider an investigator wishing to run a design II SMART in which the outcome is measured
five times, two of which are in the second stage of the trial. They might begin the simulation
process by using mean_model_prototypical() to identify the marginal means at each measurement
time from regression parameters 𝜷 as in model (3.1), which they have stored in R as a length-7
vector called betas.
means <- mean_model_prototypical(mTimes = 0:4, tStar = 2,
marginalCoefs = betas)
This returns a list containing marginal means 𝝁(𝑑) for all embedded DTRs 𝑑 as well as a data frame
identifying those embedded DTRs by first- and second-stage treatment recommendations.
The use of design_smart() requires the user specify 𝚵(𝑎1,0,1)12 (1) and 𝚵
(𝑎1,0,1)
22 (1) for both
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marginalVariances = 36 *
cormat(rho = 0.3, p = 5,
corstr = "exchangeable"),
responderMeans = list(c(33, 32), c(35, 34)),
responderVariances = list(
list(matrix(rep(10.8, 6), nrow = 3),
36 * cormat(0.3, 2, "exch")),
list(matrix(rep(10.8, 6), nrow = 3),
36 * cormat(0.3, 2, "exch"))),
threshold = c(32, 33)
)
first-stage treatments 𝑎1. The cormat() function can be of use for specifying 𝚵(𝑎1,0,1)22 (1): given a
correlation and dimension p = 𝑇2, cormat()will return a correlation matrix with the given structure:
36 * cormat(rho = 0.3, p = 2, corstr = "exchangeable")
# [,1] [,2]
# [1,] 36.0 10.8
# [2,] 10.8 36.0
Putting everything together, the user create a longsmartDesign object following the example in
program 4.3. The responderMeans argument takes a list of vectors 𝝂(𝑎1,0,1)
𝑇1+1:𝑇 (1), one element per first-
stage treatment, and responderVariances is a list of lists, where the first list contains 𝚵(1,0,1)12 (1) and
𝚵(1,0,1)22 (1) for DTRs which recommend 𝑎1 = 1, and the second is similar for 𝑎1 = −1. By default,
design_smart() uses threshold-based tailoring (see section 4.1.3); the thresholds for first-stage
treatments 𝑎1 = 1 and 𝑎1 = −1 are specified in the threshold argument.
design_smart() is highly flexible with regard to specification of a tailoring variable. The
optional responseFun argument allows the user to specify a functionwhich describes response status,
taking, at minimum, three arguments: stage1Data, a data frame containing the baseline outcome
measurement as well as potential outcomes for both first-stage treatments at all measurement
times prior to 𝑡∗; meanModel, an object describing measurement occasions and marginal means
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Program 4.4: Simulation of data from a longitudinal SMART.
d <- generate_smart(n = 300, smart = smart)
head(d$obsData, 5)
# id Y0 A1 Y1 Y2 R A2 Y3 Y4
# 1 1 35.54661 -1 29.26066 24.89015 0 -1 37.34615 45.55055
# 2 2 26.11318 1 26.04476 36.76698 1 0 42.73083 33.07181
# 3 3 34.70027 -1 40.37163 29.46754 0 -1 28.96139 41.86827
# 4 4 38.06908 -1 31.93310 24.99966 0 1 43.43282 32.37043
# 5 5 25.60596 -1 36.09325 38.32931 1 0 23.78595 39.34885
# weight dtr1 dtr2 dtr3 dtr4
# 1 4 FALSE FALSE FALSE TRUE
# 2 2 TRUE TRUE FALSE FALSE
# 3 4 FALSE FALSE FALSE TRUE
# 4 4 FALSE FALSE TRUE FALSE
# 5 2 FALSE FALSE TRUE TRUE
for all embedded DTRs at all measurement occasions; and marginalVariance, a list of marginal
variance matrices. The function then must return a data frame with potential response statuses for
each observation in stage1Data, as well as probabilities of response to each first-stage treatment.
When specifying a custom responseFun, the arguments conditionalMeanFun and conditionalVarFun
must also be provided. These return conditional means and variances, respectively, for first-stage
outcomes given response status. For threshold-based tailoring, these functions work by integrating
over the densities given in section 4.1.3.
Once a longsmartDesign object is created using design_smart(), the user can generate data
for n participants from the designed SMART using generate_smart(). An example is shown in
program 4.4. The returned object is of class longsmart, and contains all potential outcomes, the
observed data, and information about the SMART design from which the data were generated as
a longsmartDesign object. The observed data is shown above in wide format and includes both
weights and indicators for consistency with each embedded DTR (see table 2.1). d$obsData is ready
to use with the analysis method of the user’s choice.
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CHAPTER 5
Conclusions and Future Work
In this dissertation, we have developed a variety of tools for designing and analyzing sequential,
multiple-assignment randomized trials with continuous longitudinal outcomes. We pay particular
attention to the case in which the trial is designed to compare two embedded dynamic treatment
regimens which recommend different first-stage treatments. A key goal is to reduce barriers to
implementing SMARTs among clinicians and applied statisticians. To that end, we have been
keenly interested in ease-of-use.
Formulae (2.13) and (3.6) have been designed to require relatively few parameters. Those
required inputs are, we believe, relatively easy to estimate from the literature or pilot studies.
Indeed, our method requires only one additional input (𝜌) relative to formulae for SMARTs in
which the outcome is measured once at the end of the study. We described in section 2.5 that
formula (2.13) is conservative when 𝜌 is underrestimated; similarly for formula (3.6). In this way,
the methods are able to accommodate uncertainty in the investigator’s guess of the exchangeable
within-person correlation by selecting the lowest of the possible values of 𝜌.
We acknowledge and accommodate the practical realities of clinical trial design by incorporat-
ing financial considerations into the methods developed in chapter 3. We describe a search-based
approach to minimizing the total cost of recruiting participants and measuring the outcome. The
approach is based on a simple cost function, but could easily be extended to accommodate more
complex situations like incentives that change over time. The method is implemented in an easy-
to-use function in the R package longsmart. A future goal is to build a web-based sample size tool as
a companion to longsmart, which will allow us to better guide clinicians through the planning stages
of a longitudinal SMART.
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The main contribution of this dissertation is the development of sample size formulae for
SMARTs in which the primary aim is an end-of-study comparison of two embedded DTRs which
recommend different first-stage treatments (so-called “separate-path” DTRs; Kidwell and Wahed
(2013)). It is possible, though, that some trialists may have interest in sizing a SMART for an
end-of-study comparison of “shared-path” DTRs; that is, two DTRs which recommend the same
first-stage treatment. We believe that, for the comparison of shared-path DTRs, investigators
are better set to use a standard sample size calculation to compare the second-stage treatments
(conditional on response) which differ between the DTRs, then upweighting the result by the
proportion of participants expected to be in these groups.
It is important to note that while the methods described in this dissertation allow for a more
varied conversation about the design of longitudinal SMARTs, the focus of this conversation must
always be on the science. SMARTs, like other randomized trials, should be designed to address
particular scientific questions: the trial’s design should be chosen based on those questions, not the
other way around. Sample size calculations should be similarly principled. Target effect sizes, for
example, should be specified prior to choosing a sample size. This is reinforced in the design of
design_smart() in longsmart: unlike base R functions like power.t.test(), we do not allow the user
to find a detectable effect size given a sample size and power.
Statisticians should be careful to use the optimization approaches in section 3.3 in a way
that serves the investigator’s scientific interests, and not cherry-pick components of the sample
size formulae which minimize cost and/or sample size. Effort should be made to pre-specify
reasonable ranges of values for 𝜌 and response rates based on either pre-existing evidence about
the interventions under study in the SMART, or domain knowledge. Uncertainty in the choices of
these values are of course to be expected, and power curves over a range of choices are a valuable
tool; the ranges of these parameters, as well as the maximum number of measurement occasions
under consideration, should be determined by scientific, ethical, or practical considerations.
There are a number of interesting ways to build on this dissertation in future methodological
work. First, some scientists may be interested in a primary aim comparison that involves other
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features of the marginal mean trajectory, such as the area under the curve (AUC). Future work
could develop formulae for these other primary aim comparisons. An important challenge here is in
whether and how to define the standardized effect size 𝛿. We believe this would be best implemented
through software tools with graphical user interfaces that allow investigators to interactively build
and explore models for AUC. The extension of, say, formula (3.6) to other estimands is a matter of
specifying a new contrast of regression parameters, meaning we can rely on most of the derivation
in appendix B.
A second extension would be to build methods for SMARTs with intensive longitudinal
outcomes. In contrast to more traditional repeated-measures data, intensive longitudinal data (ILD)
is observed (potentially much) more frequently and can provide more detailed information on an
individual’s trajectory over time. This allows researchers to study the dynamics of behavioral or
disease processes on a much finer scale compared to a more conventional setting in which relatively
few observations are made (Hamaker and Wichers 2017).
Because of the SMART’s usefulness in constructing DTRs, which are decision rules leading
to a sequence of treatments tailored to an individual’s changing needs over time, there is increasing
interest in collecting intensive longitudinal data throughout a SMART. This would enable more
detailed assessment of the impact of treatment over time, as well as any delayed effects of treatment
that may arise as a consequence of the sequencing of interventions within a DTR. In some settings,
these effects may be quite proximal; ILD can potentially capture brief changes. An example of the
use of ILD in SMARTs is given in section 5.3 of Lu et al. (2016), in which the authors model the
outcome using regression splines. This work, particularly the details of how to incorporate design
features of a SMART into the model, is discussed only briefly, and could serve as a starting point
for meaningful future projects.
This work has been largely guided by a focus on the investigator. Ultimately, the design of a
trial is driven by the scientific questions it seeks to address. The methods in this dissertation aim to
help reduce barriers for investigators seeking to design appropriate, efficient SMARTs to address




We make the following assumptions in order to show that equation (2.6) has mean zero.
I1 Positivity. The probabilities 𝑃(𝐴1 = 1) and 𝑃(𝐴2 = 1 | 𝐴1, 𝑅) are non-zero.
I2 Consistency (Robins 1997). A participant’s observed responder status is consistent with the





And a participant’s observed repeated measures outcomes are consistent with the participant’s
corresponding potential repeated measures outcomes under the assigned treatment sequence.
For observations at measurement occasion 𝑗 in stage 𝑘 , we write 𝑌 𝑗 ,𝑖 = 𝑍𝑘 ( ?̄?𝑘 , 𝑅𝑖,𝒀 (𝑑)𝑖 ) see
table A.1. Here, “stage 𝑘” is defined such that measurement occasions 𝑗 = 1, . . . , 𝑇1 are in stage
𝑘 = 1; occasions 𝑗 = 𝑇1 + 1, . . . , 𝑇 are in stage 𝑘 = 2.
I3 Sequential randomization. At each stage in the SMART, observed treatments 𝐴1 and 𝐴2 are
assigned independently of future potential outcomes, given the participant’s history up to that
point. That is,
{𝒀 (𝑑)
𝑡≤𝑡∗ , 𝑅(𝑎1)} ⊥ 𝐴1
{𝒀 (𝑑)
𝑡>𝑡∗} ⊥ 𝐴2 | 𝐴1, 𝑅
Identifiability assumptions I1 and I3 are satisfied by design in a SMART (see, e.g., Lavori
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Table A.1: Design-specific consistency assumptions. 𝑑 ∈ D indexes embedded DTRs
(𝑎1, 𝑎2𝑅, 𝑎2𝑁𝑅).
Design Time 𝑡 𝑍𝑘 ( ?̄?𝑘 , 𝑅𝑖 ,𝒀 (𝑑)𝑖 )
I 𝑡0 𝑌 (𝑑)𝑡 ,𝑖






























II 𝑡0 𝑌 (𝑑)𝑡 ,𝑖

























III 𝑡0 𝑌 (𝑑)𝑡 ,𝑖







































The factor of 1/2 applied to some (or all) participants when 𝑡 > 𝑡∗ accounts for the
fact that these participants are consistent with two DTRs. In design I, all participants
are consistent with two DTRs. In design II, only responders are consistent with two




𝑡>𝑡∗,𝑖 . Similarly for
responders to 𝑎1 = 1 in design III.
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and Dawson (2014)); identifiability assumption I2 is connects the potential outcomes and observed




B.1 Proofs of Propositions 2.1 and 2.2
We first prove proposition 2.1, that ?̂? , the solution to equation (2.6) over 𝜽 , is asymptotically
consistent for 𝜽∗, the true regression parameter.













· 𝑫 (𝑑) (𝑿𝑖)>𝑽 (𝑑) (𝑿𝑖; 𝝉)−1
(
𝒀 𝑖 − 𝝁(𝑑) (𝑿𝑖; 𝜽)
)]
((2.6) revisited)
using data from 𝑛 individuals. Let 𝒁𝑖 contain the 𝑖th individual’s observed covariates (including
outcome, treatment assignments, etc.). We can re-write equation (2.6) as














· 𝑫 (𝑑) (𝑿𝑖)>𝑽 (𝑑) (𝑿𝑖; 𝝉)−1
(
𝒀 𝑖 − 𝝁(𝑑) (𝑿𝑖; 𝜽)
)
. (B.2)
Let ?̂?𝑛 be a solution to equation (B.2) for given 𝑛, and define 𝜽∗ as the true parameter value, such
that 𝜽∗ is a zero of Ψ(𝜽) = E[𝜓𝜽 (𝒁)].
Assuming the parameter space Θ is compact, sup𝜽∈Θ‖Ψ𝑛 (𝜽) − Ψ(𝜽)‖
𝑝
→ 0 by the weak law
of large numbers for random functions. If the model 𝝁(𝑑) (𝑿𝑖; 𝜽) is correctly specified and 𝜽∗
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is the unique solution of Ψ(𝜽) = E[𝜓𝜽 (𝒁)], then consistency follows from standard results for
𝑀-estimation of a location parameter (see, e.g., Keener (2010) Theorems 9.2, 9.4, and 9.33).
To prove proposition 2.2, consider a first-order Taylor expansion of the estimating equations
(2.6) about 𝜽∗, assuming continuous differentiability of 𝜓𝜽 :















is a 𝑝 × 𝑝 matrix, where
































Under sufficient regularity conditions (see, e.g., van der Vaart (1998) theorem 5.41), and
because ?̃?
𝑝















. By Slutsky’s theorem and the











This completes the proof.
B.2 Derivation of Sample Size Formulae for Three Measure-
ments
We derive the sample size formulae for comparing two DTRs which recommend different first-stage
treatments that are embedded in a SMART in which a continuous repeated-measures outcome is
collected throughout the study. These formulae are based on the regression analyses described
in section 2.2 and a Wald test.
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We consider a SMART in which the outcome is collected three timepoints: at baseline (𝑡 = 0),
immediately before assessing response/non-response (𝑡 = 1), and at the end of the study (𝑡 = 2).
We ignore the presence of baseline covariates 𝑿 and assume 𝝁(𝑑) (𝜽) is piecewise-linear in 𝜽 (see,
for example, model (2.1)).
Recall from section 2.3 that we wish to the null hypothesis 𝐻0 : 𝒄>𝜽 = 0. In particular, we
are interested in contrasts 𝒄 which yield an end-of-study comparison between two embedded DTRs
which recommend different first-stage treatments. Since a comparison of two embedded DTRs will








𝒄>𝑩−1𝑴𝑩−1𝒄. Under 𝐻0, by asymptotic normality of
√
𝑛(?̂? − 𝜽), the test statistic
follows an asymptotic standard normal distribution. Suppose we wish to size the SMART to detect
the alternative hypothesis 𝒄>𝜽 = Δ. By the definition of type-II error, we have
𝛽 = 𝑃
(√𝑛𝒄>?̂?𝜎𝑐



















































































where 𝑧𝑝 is the 𝑝th quantile of the standard normal distribution. Formula (B.6) is a fairly standard
result in the clinical trials literature (Lachin 1981; Friedman, Furberg, and DeMets 2010); however,
because of the dependence on 𝜎𝑐, the formula is not useful as written. The goal of this appendix is
to derive a closed-form upper bound on𝜎𝑐 so as to obtain a sample size formula in terms of marginal
quantities which can be more easily elicited from clinicians, or estimated from the literature.
Recall the definitions of 𝑩 and 𝑴 in equations (2.7) and (2.8), respectively. These quantities
depend on 𝑫 (𝑑) , the partial derivativematrix of 𝝁(𝑑) (𝜽) and𝑽 (𝑑) (𝝉), the working covariancematrix
for 𝒀 . By assumed linearity of 𝝁(𝑑) (𝜽), 𝑫 (𝑑) is a fixed, constant matrix for all 𝑑. Furthermore,
we assume that the working covariance matrix 𝑽 (𝑑) (𝝉) is correctly specified and satisfies working
assumption A2.2 so that 𝑽 (𝑑) (𝝉) = 𝚺 for all 𝑑 ∈ D. Note that 𝚺 is non-random.
The estimand in equation (2.11) is a function of potential outcomes; as written in equa-
tions (2.7) and (2.8), 𝑩 and 𝑴 are functions of observed data. We begin by expressing 𝑩 in terms
of potential outcomes. Under the positivity, consistency, and sequential ignorability conditions
(identifiability assumptions I1 to I3) and assuming that 𝑽 (𝑑) (𝝉) is correctly specified and equal to





















since 𝑫 (𝑑) and 𝚺 are non-random and E[𝑊 (𝑑) (𝐴1, 𝑅, 𝐴2)] = 1.
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Notice that the work above is design-independent: 𝑩 and 𝑴 have the same form as
equations (B.7) and (B.8), respectively, for all designs. Below, we proceed only for de-
sign II, but derivations for designs I and III are analogous, substituting appropriate definitions
of 𝑊 (𝑑) (𝐴1, 𝑅, 𝐴2). Recall that, for design II, when all randomization probabilities are 0.5,








}). Further, we restrict our focus to three
timepoints, denoted 𝑡0 (baseline), 𝑡1 = 𝑡∗, and 𝑡2 > 𝑡∗.
Consider, for example, 𝑡 = 𝑡1. By repeated use of iterated expectation and application of
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= 2(2 − 𝑟𝑎1)𝜎2. (B.13)




, equation (B.12) arises from the definition of covariance, and equation (B.13) is a consequence
of working assumption A2.1(b).
Similar derivations and applications of the remaining working assumptions allow us to bound
𝒄>𝑩−1𝑴𝑩−1𝒄 above by
𝒄>𝑩−1𝑴𝑩−1𝒄 ≤ 2 · 1
2
(













𝜌2 + 4𝜌 − 12 (𝑟1 + 𝑟−1) (2𝜌 + 1) + 2
)
1 + 𝜌 . (B.14)
Plugging equation (B.14) into formula (B.6) leads to the aforementioned “sharp” sample size
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formula for design II. Some algebra shows that







(2 − 𝑟1) + (2 − 𝑟−1)
)
, (B.15)
which allows for an easy-to-understand sample size formula. Plugging this result into formula (B.6),
we arrive at formula (2.13).
B.3 Derivation of Sample Size Formulae for Arbitrary Mea-
surements
We first establish two definitions and a lemma which will be useful for constructing an upper bound
on the variance of estimand of interest for sample size calculations.
Definition B.1 (Positive semi-definite). Let 𝑨 ∈ R𝑝×𝑝 be a 𝑝 × 𝑝 symmetric real-valued matrix.
We say 𝑨 is positive semi-definite if for any vector 𝒙 ∈ R𝑝, 𝒙>𝑨𝒙 ≥ 0.
Definition B.2 (Loewner partial order). Let 𝑨 and 𝑩 be two symmetric matrices. We say that
𝑨
𝐿
≥ 𝑩 if 𝑨 − 𝑩 is positive semi-definite.
Lemma B.1. Let 𝑨, 𝑩 be symmetric matrices. If 𝑩
𝐿
≥ 𝑨, then 𝑪>𝑩𝑪
𝐿
≥ 𝑪>𝑨𝑪 for any matrix 𝑪
of suitable dimension.
Proof. By definition B.2, 𝑩 − 𝑨 is positive semi-definite; i.e., for any vector 𝒙 of appropriate
length, 𝒙>(𝑩 − 𝑨)𝒙 ≥ 0. Let 𝒛 = 𝑪𝒙 for a suitably-sized 𝑪. Then
𝒛>(𝑩 − 𝑨)𝒛 ≥ 0
𝒙>𝑪>(𝑩 − 𝑨)𝑪𝒙 ≥ 0.
Since 𝑥 is arbitrary, 𝑪>(𝑩 − 𝑨)𝑪 is positive semi-definite by definition, completing the proof. 
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Consider a SMART in which the outcome is measured at 𝑇 occasions, labeled{
𝑡1, . . . , 𝑡𝑇−𝑇2 , . . . , 𝑡𝑇
}
, where 𝑇2 ∈ {1, . . . , 𝑇 − 2} is the number of measurements in the sec-
ond stage. As above, we can express the estimand of interest as a contrast of regression parameters
in the marginal mean models described in Section 3.1, omitting baseline covariates 𝑿𝑖. As above,
we write the estimand as a contrast of regression parameters.




(𝜷) = 𝛽0 + 1{𝑡 𝑗≤𝑡∗}
(




𝑡∗𝛽1 + 𝑡∗𝛽2𝑎1 + 𝛽3(𝑡 𝑗 − 𝑡∗) + 𝛽4(𝑡 𝑗 − 𝑡∗)𝑎1






























As before, we wish to size the study for the hypothesis test
H0 : 𝒄>𝜷 = 0 vs. H1 : 𝒄>𝜷 = Δ,






which follows an asymptotic standard normal distribution under H0 by the results in Appendix B.1.
As in appendix B.2, developing a useful sample size formula depends on obtaining a tractable
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expression for 𝒄>𝑩−1𝑴𝑩−1𝒄. With a general number of measurement occasions, the expression
for 𝑩 given in equation (B.7) holds. We now consider a more general expansion of 𝑴 which
will accommodate more than three measurement occasions. For a given 𝑑 ∈ D, define C(𝑑) ={






to be the set of DTRs which “share a path” with 𝑑. We can write
𝑴 as the sum of DTR-specific components 𝑴𝑑 and “cross-DTR” products 𝑴𝑑,𝑑 ′ for 𝑑′ ∈ C(𝑑):





















































𝒀 𝑖 − 𝝁(𝑑)
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Individuals in a SMART cannot experience treatments consistent with DTRs which do not share a
path; we will see that the definition of the weights in equation (2.5) and the identifiability indicators
in table A.1 imply that we do not need to consider cross-DTR products 𝑴𝑑,𝑑 ′ for 𝑑′ ∉ C(𝑑) as in
























}) (𝑫 (𝑑))> (𝑽 (𝑑))−1
(








































where equation (B.17) follows from equation (B.16) by identifiability assumption I2 and the fact
that 𝑫 (𝑑) is fixed when there are no baseline covariates in the model.
We now consider just the inner expectation. Recall from section 1.1 that we use 𝑆 𝑗 (𝑎 𝑗−1) to
denote information collected in the period after providing treatment 𝑎 𝑗−1 until immediately prior
to providing subsequent treatment 𝑎 𝑗 , and 𝑆 𝑗 (?̄? 𝑗−1) = {𝑆1, 𝑆2(𝑎1), . . . , 𝑆 𝑗−1(?̄? 𝑗−2), 𝑆 𝑗 (?̄? 𝑗 − 1)}
represents the “history” of observed data until the time at which 𝑎 𝑗 is recommended. Under
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𝑆2 ( ?̄?1)
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We would like to construct a simple upper bound on 𝒄>𝑩−1𝑴𝑩−1. Under working as-





1 ) = 1)
)
𝚺𝑑 . By constructing an upper bound on 𝑴, we will arrive at an upper bound
on 𝒄>𝑩−1𝑴𝑩−1𝒄 by lemma B.1.
Now, assuming that 𝑽 (𝑑) is correctly specified (i.e., 𝑽 (𝑑) = 𝚺(𝑑) = 𝚺 under working assump-















We now construct an upper bound in the Loewner sense on 𝑴𝑑,𝑑 ′ for 𝑑′ ∈ C(𝑑). For a
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We focus, as above, on the inner expectation in equation (B.20). Following the above applica-
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where equation (B.22) follows from equation (B.21) by recognizing the fact that, for responders,
DTRs 𝑑 and 𝑑′ ∈ C(𝑑) make identical treatment recommendations 𝑎1 and 𝑎2𝑅. Therefore,
responders experience these DTRs in the same way, so the potential outcomes under both should
be identical. We also drop the indicator since it evaluates to one for 𝑑 and 𝑑′ by definition of 𝑑′.


























Combining equations (B.23) and (B.19), we have







1 ) = 1)
)
𝑫 (𝑑) + 𝑫 (𝑑 ′)ª®¬ 𝑩−1𝒄. (B.24)
Recall the “clock-time” parametrization of measurement times described in section 3.1, so
91
that we may refer to measurement times 𝒖. After tedious algebra, we can write the right-hand side
of equation (B.24) as
𝜎2(1 − 𝜌) (1 + (𝑇 − 1)𝜌)








(6 − 𝑟1 − 𝑟−1)
(













where 𝑟𝑎1 = 𝑃(𝑅(𝑎1) = 1), 𝑟 = (𝑟1+𝑟−1)/2, 𝑠𝑘 =
∑𝑇





1 + (𝑇 − 1)𝜌
) 𝑇∑︁
𝑗=1













= (1 − 𝜌) (1 + (𝑇 − 1)𝜌) ·
𝑢22𝑇𝑔1(𝜌) + 𝑢
2





Equation (B.26) simplifies to equation (3.7) under working assumption A3.3. We arrive at
formula (3.6) by plugging equation (B.25) into formula (B.6).
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APPENDIX C
Further Exploration of the Within-Person Deflation
Factor














where 𝑟𝑎1 = 𝑃(𝑅(𝑎1) = 1), 𝑟 = (𝑟1+𝑟−1)/2, 𝑠𝑘 =
∑𝑇





1 + (𝑇 − 1)𝜌
) 𝑇∑︁
𝑗=1








We show that 𝜔 (0, 𝒖, 1) = 1 for any measurement times 𝒕. Here, note that ℎ1(0) = 𝑢1𝑇 , 𝑠2 =∑𝑇








2 𝑗 = 𝑢
2
2𝑇 . Plugging in to equation (B.26),
we have




























when we do not make working assumption A3.3,
i.e., whenmeasurement times are not equally spaced in each stage. To do this, we recreate figure 3.2,
this time adding noise to the measurement times 𝒕. We keep 𝑡1, 𝑡𝑇1 = 𝑡∗, and 𝑡𝑇 fixed. For other
measurements, we add uniformly-distributed noise to the equally-spaced times so that the 𝑡 𝑗 take




are depicted in figure C.1.






































































































































































































when working assumption A3.3 is violated. The function is
bounded above by 1 for all 𝜌, 𝑇 , and 𝑇2, demonstrating that it is in fact a deflation factor. The function tends to decrease
with 𝑇 , but is quite jagged when 𝑇 is large relative to 𝑇2.
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are not equally-spaced. Generally, we still see the trends discussed in section 3.2; namely, as 𝜌,
𝑇 and 𝑇2 increase, the deflation factor tends to decrease, with 𝜔 still obtaining a minimum on the
interior of the domain of 𝑇2 for large values of 𝑇 . We conjecture that some or all of the jaggedness
in figure C.1 arises from the fact that we are not “adding” measurement occasions to the SMART:
each point in each plot is for a different set of measurement times 𝒕.
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